NZ719720B2 - Engineered human t cell receptors with high affinity for wt1 - Google Patents

Abstract

cell receptors (TCRs) that have specificity for the WT1 antigen are provided. The TCRs include higher affinity TCRs that were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting. t (i.e. directed evolution). In embodiments, the TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

Description

ENGINEERED HUMAN T CELL ORS WITH HIGH TY FOR WT1 CROSS-REFERENCE TO D APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S.

Provisional Patent Application No. 61/907,887 filed November 22, 2013, and this provisional application is incorporated herein by reference in its entirety.

STATEMENT REGUARDING FEDERALLY SPONSORED CH OR DEVELOPMENT This disclosure was made with U.S. Government support under Grant numbers R01 GM55767 and T32 GM070421, awarded by the National Institutes of Health. The U.S. Government has certain rights in the disclosure.

STATEMENT REGARDING SEQUENCE LISTING The Sequence g associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file ning the Sequence Listing is IMMU_003_02WO_ST25.txt. The text file is 18 KB, was created on November 21, 2014 and is being submitted electronically via b.

FIELD OF THE INVENTION The disclosure relates to T cell receptors (TCR) against the Wilms' tumor antigen (WT1), ing high-affinity TCRs engineered by in vitro techniques, as well as methods of producing modified TCRs and single-chain TCRs and the ponding uses of the TCRs for therapeutic, diagnostic, and imaging methods.

BACKGROUND T cell receptors (TCRs) and antibodies are molecules that have evolved to recognize different classes of antigens (ligands)((Murphy (2012), xix, 868 p.)). TCRs are antigen-specific molecules that are responsible for recognizing antigenic peptides presented in the context of a product of the major histocompatibility complex (MHC) on the surface of antigen ting cells (APCs) or any nucleated cell (e.g., all human cells in the body, except red blood cells). In contrast, antibodies typically recognize soluble or cell-surface ns, and do not require presentation of the antigen by an MHC. This system endows T cells, via their TCRs, with the potential ability to ize the entire array of intracellular antigens sed by a cell (including virus ns) that are processed intracellularly into short peptides, bound to an intracellular MHC molecule, and delivered to the surface as a peptide- MHC complex (pepMHC). This system allows virtually any foreign protein (e.g., mutated cancer antigen or virus protein) or aberrantly expressed protein to serve a target for T cells (reviewed in (Davis and Bjorkman (1988) Nature, 334, 395—402; Davis et al. (1998) Annu Rev Immunol, 16, 523—544; Murphy (2012), xix, 868 p.)).

The interaction of a TCR and a pepMHC can drive the T cell into various states of activation, depending on the affinity (or dissociation rate) of binding. The TCR recognition process allows a T cell to discriminate between a normal, healthy cell and, e.g., one that has become transformed via a virus or malignancy, by providing a diverse repertoire of TCRs, wherein there is a high probability that one or more TCRs will be t with a binding ty for the foreign peptide bound to an MHC molecule that is above the threshold for stimulating T cell activity (Manning and Kranz (1999) logy Today, 20, 417-422).

To date, wild type TCRs isolated from either human or mouse T cell clones that were identified by in vitro culturing have been shown to have relatively low binding affinities (Kd = 1 — 300 uM) (Davis et al. (1998) Annu Rev Immunol, 16, 523- 544). Part of the explanation for this seems to be that T cells that develop in the thymus are negatively ed (tolerance induction) on self-pepMHC ligands, such that T cells with too high of an affinity are deleted (Starr et al. (2003) Annu Rev Immunol, 21, 139-76). To compensate for these relatively low affinities, T cells have evolved a co-receptor system in which the cell surface molecules CD4 and CD8 bind to the MHC les (class II and class I, tively) and ize with the TCR in mediating signaling activity. CD8 is particularly effective in this process, allowing TCRs with very low affinity (e.g.,Kd =300 uM) to mediate potent antigen-specific activity.

In vitro, directed evolution has been used to generate TCRs with higher affinity for a specific pepMHC. The three different display methods that have been used are yeast display (Holler et al. (2003) Nat Immunol, 4, 55-62; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387-92), phage display (Li et al. (2005) Nat Biotechnol, 23, 349-54), and T cell display (Chervin et al. (2008) J Immunol s, 339, 175-84). In all three approaches, the process involves engineering, or modifying, a TCR that ts the normal, low affinity of the wild—type TCR, so that affinity of s of the TCR have increased affinity for the cognate pepMHC (the original antigen that the T cells were specific for). Thus, the wild-type TCR was used as a template for producing mutagenized libraries in one or more of the CDRs, and mutants with higher affinity were selected by binding to the cognate peptide-MHC anfigen.

In the present disclosure, a wild-type T cell receptor and high affinity T cell receptors specific for the Wilm’s Tumor-1 (WT1) engineered by yeast y are disclosed. WT1 is a transcription factor that has been described to function both as a tumor suppressor and an oncogene. WT1 is expressed at high levels in leukemia as well as a variety of solid tumors (Sugiyama et al. (2010) se Journal of Clinical gy 40(5) 377-387). It has been the target of vaccine efforts, and various adoptive T cell approaches using T cells with wild-type T cell receptors.

WT1 has been ranked number 1 in a prioritization list of the top 75 cancer antigens by the National Cancer Institute er et al. (2009) Clin Cancer Res, 15, 5323—5337). Accordingly, there is a need to identify agents, e.g., therapeutic agents, that specifically target this cancer n. The present ion provides in vitro engineered, higher affinity TCRs that can be used, e.g., in soluble form for targeted delivery in vivo or as genes introduced into T cells in an adoptive T cell setting.

SUMMARY OF THE INVENTION The present invention relates to a wild-type T cell receptor against the WT1 n, and in vitro engineered T cell receptors (TCR) that bind to the WT1 antigen with improved affinity. More ically, the present disclosure relates to the sequences of the wild—type T cell receptor and those stabilizing and affinity mutations selected h the display of libraries on the surface of yeast, phage, or mammalian cells; to TCR proteins selected from these libraries for binding to an antigen with increased affinity; and to the use of in vitro selected TCR derivatives for therapeutic, diagnostic, or g applications.

One aspect of the invention relates to a T cell receptor, or antigen-binding nt thereof, comprising a Va and a VB derived from a T cell clone, wherein the T cell receptor binds to a complex of the peptide WT1 and the HLA—A2 molecule, and wherein the T cell receptor comprises the VB amino acid ce set forth in SEQ ID NO:1 and the Va amino acid sequence set forth in SEQ ID NO:2. In one embodiment, a host cell that expresses the T cell receptor. In a further embodiment, the host cell is a human T cell.

One aspect of the invention elates to a modified T cell receptor, or antigen binding fragment thereof, comprising a Va and a VB derived from a wild type T cell receptor, wherein the V0, the VB, or both, se a mutation in one or more complementarity determining regions (CDRs) relative to the wild type T cell or, wherein the modified T cell receptor binds to the peptide/MHC antigen known as WT1/HLA-A2 (the WT1 peptide RMFPNAPYL (SEQ ID NO:6), bound to the MHC product known as HLA-A2).

In one embodiment, the T cell receptor comprises a VB comprising an amino acid sequence having at least 80% identity to the VB amino acid sequence set forth in SEQ ID NO:1, wherein the T cell receptor mediates activity by binding to WT1/H LA-A2.

In another embodiment, the modified T cell receptor comprises a ed VB comprising an amino acid sequence having at least 80% identity to the VB amino acid sequence set forth in SEQ ID NO:3, wherein the modified T cell receptor binds to WT1/HLA-A2 with an affinity (KA value) of 106 M higher.

In another embodiment, the T cell receptor comprises a Va comprising an amino acid sequence having at least 80% identity to the Va amino acid sequence set forth in SEQ ID NO:2, wherein the T cell receptor es activity by binding to A-A2.

In another embodiment, the modified T cell receptor comprises a modified Va comprising an amino acid sequence having at least 80% ty to the Va amino acid sequence set forth in SEQ ID NO:4, n the modified T cell receptor binds to WT1/HLA-A2 with an affinity (KA value) of 106 M higher.

In one embodiment, the T cell receptor is a single-chain T cell receptor sing the amino acid sequence set forth in SEQ ID NO:5.

In one embodiment, the T cell or ns at least one of the mutations in CDR3B selected from 895T, 897N, l103Y, N104L of the amino acid sequence set forth in SEQ ID NO:3.

In another embodiment, the T cell receptor contains at least one of the mutations in CDR1a selected from V29D, SBOL, and Q31 G of the amino acid sequence set forth in SEQ ID NO:4.

In one embodiment, the modified T cell receptor is generated by in vitro selection of a yeast display library of mutant T cell receptors.

In r embodiment, the modified T cell receptor is expressed as a soluble protein that binds to its target antigen.

In another embodiment, the wild-type or the modified T cell ors are expressed in T cells for adoptive T cell therapies.

One aspect of the invention provides a therapeutic agent that targets cancer cells that express the WT1 antigen, wherein the therapeutic agent comprises a modified T cell receptor described herein. In one embodiment, a eutic agent that targets cancer cells that express the WT1 antigen, wherein the therapeutic agent ses a human T cell that expresses a modified T cell receptor described herein. One ment provides a method of treating a subject having a cancer that expresses the WT1 antigen comprising administering a therapeutic agent described herein.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the aligned amino acid sequences of various WT1/HLA—A2 ic T cell receptors from the present study. WT1 P22 represents the wild-type sequence ed from a human T cell clone that was stimulated by WT1/HLA-A2.

The other TCR sequences were ed by yeast display methods for greater surface levels and for higher affinities. The amino acid residues within the CDR3[3 and the CDR10i that are highlighted within rectangles were mutations in TCRs isolated for higher affinity by yeast display. The sequences shown for the VB chain correspond to SEQ ID NOs:1, 21, 21, 3, and 3, from top to bottom. The linker sequence depicted is SEQ ID N028. The sequences shown for the V0. chain pond to SEQ ID NOs:2, 22, 4, 2, and 4, from top to bottom.

Figure 2A is a nsional diagram that shows a side view of the TCR:pepMHC complex (A6; PDB:1AO7). The variable (V) and constant (C) regions of the d-chain and B-chain are indicated. The structure shown does not include the Ca region of the TCR. HLA-A2 (d1, d2, (13, and 62m) is shown in gray, and the Tax peptide (LLFGYPVYV, SEQ ID NO:7) is shown in black. The A6 TCR and the WT1 TCRs examined in the present ion all use the V02 segment (also referred to as TRAV12 based on IMGT nomenclature).

Figure 2B is a 3-dimensional m that shows the top down view of the TCR (CDR) footprint over the peptide-MHC LA-A2). Although no crystal structures have been described for the WT1 TCR used in the present disclosure, this diagonal docking orientation, with the V0 region oned over the (12 MHC helix and the N—terminal end of the peptide, and the V6 region positioned over the G1 MHC helix and C-terminal end of the peptide, has been observed in virtually all complexes to date.

Figure 3 is a diagram that shows a method for engineering single chain TCRs for improved affinity against a peptide:HLA.A2. The general process used to engineer high affinity TCRs is shown.

Figure 4 is a schematic of the yeast-display system for engineering single- chain T cell receptor fragments (Va-linker VB or VB-linker—Va).

Figures 5A and SB show the flow cytometry histograms of the WT1 single- chain TCR error prone library after sorting with two antibodies which recognize conformation epitopes on V63. The WT1 error prone library was sorted sequentially with a 1:10 on of both Therma th3.1 FITC lgG and BC th3.2 FITC lgM antibodies, luor 647 Goat anti-mouse lgG and Goat anti-mouse lgM APC, for a total of 3 sorts. Aliquots of yeast cells after each sort were then incubated with a 1:10 dilution of Therma th3.1 FITC lgG, luor 647 Goat anti—mouse lgG.

Gray indicates yeast cells stained with secondary antibody only (Figure 5A). The stable clone WT1 D13, isolated after the 3rd sort, is d with a 1:10 dilution of Therma th3.1 FITC lgG, AlexaFluor 647 Goat anti-mouse lgG (Figure 5B).

Figures 6A and 6B show the flow cytometry rams of the WT1 - chain TCR D13 CDR1a library after sorting with WT1:HLA.A2. The WT1 D13 CDR1or library was sorted sequentially with 100-200 nM WT1:HLA-A2 dimer (DimerX; obtained from BD Pharmingen), APO-conjugated goat anti-mouse secondary antibody, for a total of five sorts. Aliquots of yeast cells after each sort were then incubated with 100 nM WT1:HLA-A2 dimer (DimerX; obtained from BD Pharmingen), followed by njugated goat anti-mouse secondary antibody. Gray indicates yeast cells stained with secondary antibody only (Figure 6A). Clone WT1 D13.1, isolated after the 5th sort, is stained with 100 nM WT1:HLA-A2 dimer (DimerX; obtained from BD Pharmingen), followed by APO-conjugated goat ouse secondary antibody (Figure 6B). s 7A and 7B show the flow cytometry rams of the WT1 single- chain TCR D13.1 combined CDR3 library after g with WT1:HLA.A2. The WT1 D13.1 combined CDR3 library was sorted sequentially with 10-100 nM WT1:HLA—A2 dimer (DimerX; obtained from BD Pharmingen), APC-conjugated goat anti-mouse secondary antibody, for a total of three sorts. Aliquots of yeast cells after each sort were then incubated with 100 nM WT1:HLA-A2 dimer (DimerX; obtained from BD Pharmingen), followed by APO—conjugated goat anti-mouse secondary antibody.

Gray indicates yeast cells stained with secondary antibody only (Figure 7A). The improved binding clone WT1 D13.1.1, isolated after the 3rd sort, is stained with 100 nM WT1:HLA-A2 dimer (DimerX; obtained from BD Pharmingen), followed by APC- conjugated goat anti-mouse secondary antibody (Figure 7B).

Figures 8A-8D show the binding properties of a high-affinity TCR, WT1 1, for WT1:HLA-A2 dimers and monomers. Figure 8A shows the flow cytometry histograms of the high affinity scTCR WT1 D13.1.1 stained with various concentrations of WT1 :HLA-A2 lg dimer, followed by fluorescent labeled g antibody as a secondary. Figure 8B shows the flow try histograms of the high affinity scTCR WT1 D13.1.1 d with various concentrations of biotinylated WT1:HLA-A2 monomer, followed by SA-PE (1:100) secondary. Figure 8C is a line graph that shows mean fluorescence intensity (MFI) values of histograms in Figure 7A plotted versus WT1:HLA-A2 dimer concentration. Figure 8D is a line graph that shows mean fluorescence ity (MFI) values of histograms in Figure 8B plotted versus WT1:HLA-A2 monomer tration.

Figures 9A-E show the binding of e high-affinity TCR WT1 D13.1.1 that was sed in E. coli. Figures 9A-D are a series of histograms that show flow cytometry analysis of human T2 (HLA—A2+) cells incubated first with no peptide e 9A), negative control peptide Tax (Figure QB), negative control peptide MART-1 (Figure 9C), or peptide WT1 (Figure 9D), followed by incubation with biotin- labeled WT1-D13.1.1 TCR. Figure SE is a graph that depicts the titration showing that the WT1-D13.1.1 TCR had a minimum affinity (KD value) of at least 260 nM (as washing of cells in flow cytometry results in an underestimate of affinities in this range).

Figures 10A and 108 show the activity of wild—type P22, D13.1, D13.0.1 and D13.1.1 TCRs in mouse T cells. Isolated mouse CD8 (Figure 10A) and CD4 (Figure 108) T cells were transduced with P22, D13.1, D13.0.1 and D13.1.1 TCRs (modified TCRs did not contain the D13 “stabilizing” mutations in the VB region: F488 and D51G). Transduced T cells were then incubated with HLA-A2+ APCs and various concentrations of the WT1 peptide. Following 24 hours tion, IFN-y concentrations were measured using a standard ELISA.

Figure 11 shows that the high—affinity TCR WT1 D13.1.1 in CD8 T cells did not show activity against a panel of WT1 structurally similar human es. WT1 structurally similar peptides were determined through searches of the human proteome for peptides with conservative mutations at each of the 9 residues of the WT1 peptide (SEQ ID NO:6). The 10 peptides that were ted to bind to HLA-A2 with highest affinity were then synthesized. Peptide numbers 1-10 correspond to SEQ ID NOs:25-34, respectively. Mouse CD8 T cells were isolated and transduced with the D13.1.1 TCR (did not contain D13 stabilizing mutations in VB , F488 and D51 G) and incubated for 24 hours with respective peptides and HLA-A2+ APCs.

Figures 12A and 12B are diagrams that illustrates exemplary therapeutic applications of the WT1-specific TCRs. Figure 12A depicts five examples of TCR s for use as soluble therapeutic ts: 1) -chain TCR in either a Vor— VB orientation or VB-Va orientation (mutated high-affinity V domains are shown with an asterisk); 2) -chain TCR fused in frame with the constant region domains of an antibody; 3) in—frame immunoglobulin fusion to either the constant region of the light chain or the heavy chain; 4) single-chain TCR (or the immunoglobulin fusions shown in 2 and 3) directly coupled to a drug; and 5) single—chain TCR linked in—frame with a single-chain Fv (VL-linker—VH) to generate a bispecific agent. Figure 128 depicts two es of cellular based therapies that would use the ffinity variable domains (V) isolated by yeast display, or the ype TCR V domains may also be used for adoptive T cell therapies with human T cells). The TCRs are cloned into mammalian cell vectors, for expression by T cells in adoptive T cell therapy as: 1) single-chain receptors in chimeric antigen receptors (CAR) and 2) full length or and [3 TCRs.

BRIEF DESCRIPTION OF THE SEQUENCES SEQ ID NO:1 is the amino acid sequence of a wild-type V0 region of the TCR (P22) that binds to WT1/HLA-A2.

SEQ ID NO:2 is the amino acid sequence of a wild-type Vor region of the TCR (P22) that binds to WT1/HLA-A2.

SEQ ID NO:3 is the amino acid sequence of a modified V0 region of the TCR (D13.1.1) that binds with high-affinity to WT1/HLA-A2.

SEQ ID NO:4 is the amino acid sequence of a ed Vor region of the TCR (D13.1.1) that binds with high-affinity to WT1/HLA-A2.

SEQ ID NO:5 is the amino acid ce of a single-chain TCR (WT1- D13.1.1) that binds with high-affinity to WT1/HLA-A2.

SEQ ID NO:6 is the amino acid sequence of the WT-1 antigen.

SEQ ID NO:7 is the amino acid sequence of the Tax n.

SEQ ID NO:8 is the amino acid sequence of the .

SEQ ID NO:9 is the is the polynucleotide sequence of the primer Splice SEQ ID NO:10 is the is the polynucleotide sequence of the reverse primer used to generate the WT1-D13 CDR10L library PreSOE #1 .

SEQ ID NO:11 is the is the polynucleotide sequence of the forward primer used to generate the WT1-D13 CDR1a library PreSOE #2.

SEQ ID NO:12 is the is the polynucleotide sequence of the primer T7.

SEQ ID NO:13 is the is the polynucleotide sequence of the reverse primer used to generate the PreSOE #1 of the WT1-D131 CDR3 [51 library SEQ ID NO:14 is the is the polynucleotide sequence of the forward primer used to generate the PreSOE #2 of the WT1-D131 CDR3 B1 library SEQ ID NO:15 is the the polynucleotide ce of the reverse primer used to generate the PreSOE #1 of the WT1-D13.1 CDR3 [32 library.

SEQ ID NO:16 is the is the polynucleotide ce of the fon/vard primer used to generate the PreSOE #2 of the WT1-D13.1 CDR3 [32 library.

SEQ ID NO:17 is the the polynucleotide sequence of the reverse primer used to generate the PreSOE #1 of the 3.1 CDR3 of y SEQ ID NO:18 is the is the polynucleotide sequence of the forward primer used to generate the PreSOE #2 of the WT1-D13.1 CDR3 of library SEQ ID NO:19 is the is the polynucleotide sequence of the reverse primer used to generate the PreSOE #1 of the WT1-D13.1 CDR3 02 library SEQ ID NO:20 is the is the polynucleotide sequence of the fon/vard primer used to generate the PreSOE #2 of the WT1-D13.1 CDR3 a2 library.

SEQ ID NO:21 is the amino acid sequence of a modified V0 region of the TCR (D13) that binds with high-affinity to WT1/HLA-A2.

SEQ ID NO:22 is the amino acid sequence of a modified Vor region of the TCR (D13) that binds with high-affinity to WT1/HLA-A2.

SEQ ID NO:23 is the amino acid sequence of an influenza A peptide.

SEQ ID NO:24 is the amino acid sequence of a variant influenza A peptide.

SEQ ID NOs:25-34 are the amino acid sequences often WT1 variant peptides.

DETAILED DESCRIPTION The ing description is intended to facilitate understanding of the disclosure but is not intended to be limiting.

In general, the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art. The following definitions are provided to clarify their ic use in the context of the disclosure.

As used herein, “linked” refers to an association n two groups, which can be a covalent or non—covalent association. Groups may be linked using a variable length peptide chain, a non-amino acid chemical group or other means as known in the art. A linker region can be an amino acid ce that operably links two functional or structural domains of a protein or peptide.

As used herein, the term “chemotherapeutic agent” refers to any nce capable of reducing or ting the growth, proliferation, or spread of a cancer cell, a population of cancer cells, tumor, or other malignant tissue. The term is intended also to encompass any antitumor or anticancer agent.

As used herein, the term “effective amount” is intended to encompass contexts such as a pharmaceutically effective amount or eutically effective amount. For example, in certain embodiments, the effective amount is capable of achieving a beneficial state, beneficial outcome, functional activity in a screening assay, or improvement of a al condition.

As used herein, the term “cancer cell” is intended to encompass definitions as broadly understood in the art. In one embodiment, the term refers to an abnormally regulated cell that can contribute to a clinical condition of cancer in a human or animal. In one embodiment, the term can refer to a cultured cell line or a cell within or derived from a human or animal body. A cancer cell can be of a wide variety of differentiated cell, tissue, or organ types as is understood in the art.

Particular examples of cancer cells include breast cancer, colon cancer, skin cancer, ovarian cancer, leukemia, lung cancer, liver cancer, testicular cancer, esophageal cancer, and other types of cancer.

As used herein, “treating” or “treatment” refers to an ch for obtaining beneficial or d results, ing and preferably clinical results.

Treatment can refer to either the amelioration of ms of the disease or condition, or the ng of the ssion of the e or ion.

As used herein, "prevention" or “preventing” refers to an approach for preventing, inhibiting, or reducing the likelihood of, the onset or recurrence of a disease or condition. It also refers to preventing, inhibiting, or reducing the likelihood of, the occurrence or recurrence of the ms of a disease or condition, and it also includes reducing the intensity, effect, symptoms and/or burden of a disease or condition prior to onset or recurrence of the disease or condition.

As used herein, “inhibiting cell growth” or “inhibiting proliferation of cells” refers to reducing or halting the growth rate of cells. For example, by inhibiting the growth of tumor cells, the rate of increase in size of the tumor may slow. In other embodiments, the tumor may stay the same size or se in size, i.e., regress.

In particular embodiments, the rate of cell growth or cell proliferation is inhibited by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

The terms “wild type” and “wt” are used interchangeably herein and are used in reference to a TCR having an amino acid sequence or a polynucleotide encoding the variable regions ed from a naturally occurring or non-modified TCR, e.g., the original or parent T cell clone, with specificity for the antigen.

In the figures and tables that present amino acid sequences, the wild type is sometimes designated “wt”. In the sequences presented below the top sequence, a dash indicates the amino acid is the same as that present in the wt or top sequence of the alignment. A letter indicates a substitution has been made in that position from the top sequence.

As used herein, the terms “modified”, “variant, , mutated” and “derived” T cell receptor refer to TCR ces of the le regions having one or more mutations compared to the original or wild type T cell clone. Examples of modified TCRs include higher affinity TCRs.

A coding sequence is the part of a gene or cDNA which codes for the amino acid sequence of a protein, or for a functional RNA such as a tRNA or rRNA.

Complement or complementary ce means a sequence of tides that forms a hydrogen-bonded duplex with another sequence of nucleotides according to Watson-Crick base-pairing rules.

Downstream refers to a relative position in DNA or RNA and is the region toward the 3' end of a strand.

Expression refers to the ription of a gene into structural RNA (rRNA, tRNA) or messenger RNA (mRNA) and subsequent translation of an mRNA into a protein.

Two nucleic acid sequences are heterologous to one another if the ces are derived from separate organisms, whether or not such organisms are of different species, as long as the sequences do not naturally occur together in the same arrangement in the same organism.

Homology refers to the extent of identity between two nucleotide or amino acid sequences.

An amino acid sequence that is onally equivalent to a specifically exemplified TCR ce is an amino acid sequence that has been modified by single or multiple amino acid substitutions, by addition and/or deletion of amino acids, or where one or more amino acids have been chemically modified, but which nevertheless retains the binding specificity and high affinity binding activity of a cell bound or a soluble TCR protein of the t disclosure. Functionally equivalent nucleotide sequences are those that encode polypeptides having substantially the same biological activity as a specifically exemplified cell—bound or soluble TCR n. In the context of the present disclosure, a soluble TCR protein lacks the portions of a native cell—bound TCR and is stable in solution (i.e., it does not generally aggregate in solution when d as described herein and under standard ions for protein solutions).

The term “isolated” refers to a composition, compound, substance, or molecule altered by the hand of man from the natural state. For e, a composition or substance that occurs in nature is isolated if it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally t in a living animal is not isolated, but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is isolated, as the term is employed herein.

A nucleic acid construct is a nucleic acid molecule which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.

Nucleic acid molecule means a single— or double—stranded linear polynucleotide containing either deoxyribonucleotides or ribonucleotides that are linked by phosphodiester bonds.

Two DNA sequences are operably linked if the nature of the linkage does not interfere with the ability of the sequences to affect their normal functions relative to each other. For instance, a promoter region would be operably linked to a coding sequence if the promoter were capable of effecting transcription of that coding sequence.

A polypeptide is a linear polymer of amino acids that are linked by peptide bonds.

The term “promoter” refers to a cis-acting DNA sequence, generally 80- 120 base pairs long and located upstream of the initiation site of a gene, to which RNA polymerase may bind and te t transcription. There can be associated additional transcription regulatory sequences which e on/off regulation of transcription and/or which e (increase) expression of the downstream coding sequence.

A recombinant nucleic acid molecule, for instance a inant DNA molecule, is a novel nucleic acid sequence formed in vitro through the on of two or more nonhomologous DNA molecules (for example a recombinant plasmid containing one or more inserts of foreign DNA cloned into at least one g site).

The terms “transformation” and “transfection” refer to the directed modification of the genome of a cell by the external application of purified recombinant DNA from another cell of different genotype, leading to its uptake and ation into the subject cell’s genome. ln bacteria, the inant DNA is not typically integrated into the bacterial chromosome, but d replicates autonomously as a d. The terms “transformed” and “transfected” are used interchangeably herein. For example, a T cell may be transfected with a DNA sequence encoding a modified or high affinity TCR bed herein prior to adoptive T cell treatment.

Upstream means on the 5' side of any site in DNA or RNA.

A vector is a nucleic acid molecule that is able to replicate autonomously in a host cell and can accept foreign DNA. A vector carries its own origin of replication, one or more unique recognition sites for restriction endonucleases which can be used for the insertion of foreign DNA, and usually selectable markers such as genes coding for antibiotic resistance, and often ition sequences (e.g.,promoter) for the expression of the inserted DNA. Common vectors include plasmid vectors and phage vectors.

A high affinity T cell receptor (TCR) is an engineered TCR with stronger binding to a target ligand than the wild type TCR. Some es of high affinity include an equilibrium binding constant for a target ligand of between about 10'6 M and 10'12 M and all individual values and ranges therein. This range encompasses affinities between those reported to be wild type affinities (10'4 to 10'6 M), and those which have been isolated by directed evolution (about 10'12 M).

A cytokine is a protein, e or glycoprotein made by cells that affect other cells.

Mammal includes both human and non-human mammals.

It will be appreciated by those of skill in the art that, due to the degeneracy of the genetic code, numerous functionally equivalent nucleotide sequences encode the same amino acid sequence.

T Cell Receptors The T cell receptor (TCR) is composed of two chains (a8 or y8) that pair on the surface of the T cell to form a heterodimeric receptor. The dB TCR is expressed on most T cells in the body and is known to be involved in the recognition of MHC- cted antigens. The molecular genetics, structure, and biochemistry of a8 TCRs have now been studied thoroughly. Each or and [3 chain is composed of two domains: Constant domains (C) that anchor the protein in the cell membrane and that associate with invariant subunits of the CD3 signaling apparatus, and Variable domains (V) that confer antigen ition h six loops, called complementarity determining regions (CDR). Each of the V domains has three CDRs. These CDRs interact with a complex between an antigenic peptide bound to a protein encoded by the major histocompatibility complex (pepMHC) (Davis and Bjorkman (1988) Nature, 334, 2; Davis et al. (1998) Annu Rev Immunol, 16, 523-544; Murphy (2012), xix, 868 p.).

The molecular genetics of the TCR have revealed a s of genetic recombination between multiple genes that combine to form the coding region of the V domains. The process is analogous to antibody development in which the heavy and light chain genes rearrange to generate the tremendous diversity exhibited by B cell-derived antibodies (Tonegawa (1988) In Vitro Cell Dev Biol, 24, 253-65). In the case of T cells, the or chain V domain is formed by the rearrangement of one V region (among about 75 in humans) to one Joining (J) gene segment (among about 61 in ) e 5.8, Janeway, 8th edition). The [3 chain V domain is formed by the rearrangement of one V region (among about 52 in humans) to one Diversity (D) gene (among 2 in humans) to one Joining (J) gene segment (among 13 in humans) (Figure 5.8, (Murphy (2012), xix, 868 p.)). The ons of the VorJor and VBDBJB gene ngements encode the CDR3 loops of each chain, and they contribute to the tremendous diversity of the (18 TCR, with a theoretical limit of over 1015 different TCRs (Davis and Bjorkman (1988) Nature, 334, 395-402), well above the able diversity in a human because there are only about 1011 T cells total (Mason (1998) Immunol Today, 19, 395-404). The possible CDR1 and CDR2 diversity of each chain is represented by the number of V genes, as these loops are encoded within the V gene, and TCRs do not undergo somatic on in vivo. Although the diversity of CDR1 and CDR2 loops are relatively limited compared to CDR3 loops, there have been a number of examples shown where there has been selection for particular V regions based on the peptide antigen and/or MHC product.

Class | MHC products bind to es of 8 to 10 amino acids in length and they are expressed on all ted cells in the body (reviewed by (Rock and rg (1999) Annu Rev Immunol, 17, 739-79)). s all the binding energy of an antibody-antigen interaction is focused on the foreign antigen, a substantial fraction of the binding energy of the TCR-peptide:MHC is directed at the self-MHC le (Manning and Kranz (1999) Immunology Today, 20, 417—422). In fact, more recent studies have suggested that particular residues of the CDR1 and/or CDR2 loops have evolved to interact with particular es on the MHC helices, y providing a basal affinity for MHC, accounting for the s of MHC—restriction (Garcia et al. (2009) Nat l, 10, 143-7; Marrack et al. (2008) Annu Rev Immunol, 26, 171-203).

There has been interest in using TCRs that have affinities for a peptide- MHC antigen (class I) above the normal range (so called higher affinity TCRs) in order to: 1) drive the activity of CD4 helper T cells (which lack the CD8 ptor) or 2) develop soluble TCRs that could be used for direct targeting of a cell, by attaching an “effector” molecule (e.g., antibody Fc regions, a toxic drug, or an antibody scFv such as an anti-CD3 antibody, to form a ific protein)((Ashfield and Jakobsen (2006) lDrugs, 9, 554-9; Foote and Eisen (2000) Proc Natl Acad Sci USA, 97, 10679-81; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387-92; Molloy et al. (2005) Curr Opin Pharmacol, 5, 438—43; Richman and Kranz (2007) Biomol Eng, 24, 361-73). This approach also could overcome a problem faced by some cancer patients, whereby their T cells do not express TCRs with adequate specificity and binding affinity to potential tumor antigens (in part due to the thymic and peripheral ses of tolerance). For example, over 300 MHC-restricted, T cell—defined tumor antigens have now been identified (cancerimmunity.org/peptide/)(Boon and Old (1997) Curr Opin Immunol, 9, 681-3; Cheever et al. (2009) Clin Cancer Res, 15, 5323-37). These tumor antigens include mutated peptides, differentiation antigens, and overexpressed antigens, all of which could serve as targets for therapies. Because the majority of the cancer antigens described to date were derived from intracellular proteins that can only be targeted at the cell surface in the context of an MHC molecule, TCRs make the ideal candidate for therapeutics as they have evolved to recognize this class of antigen.

Similarly, TCRs can detect peptides derived from viral proteins that have been naturally processed in infected cells and displayed by an MHC molecule on the cell e. Many viral antigen targets have been identified over the past 25 years, including peptides d from viral genomes in HIV and HTLV (e.g., Addo et al. (2007) PLoS ONE, 2, e321; Tsomides et al. (1994) J Exp Med, 180, 3; Utz et al. (1996) J Virol, 70, 843-51). However, patients with these diseases may lack the optimal TCRs for binding and destruction of the infected cells. Finally, it is possible that TCRs could be used as receptor antagonists of autoimmune targets, or as delivery agents to immunosuppress the local immune cell response, in a process that would be highly specific, thereby avoiding l immune suppression ((Molloy et al. (2005) Curr Opin Pharmacol, 5, 438-43; Stone et al. (2012) Protein Engineering)).

Modified T Cell Receptors ed evolution has been used to generate TCRs with higher affinity for a specific pepMHC. The three different display methods that have been used are yeast display (Holler et al. (2003) Nat l, 4, 55-62; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 2), phage display (Li et al. (2005) Nat Biotechnol, 23, 349-54), and T cell display in et al. (2008) J Immunol Methods, 339, 175-84).

In all three approaches, the process involves the engineering of a TCR that exhibits the normal, low ty of the wild-type TCR, so mutants of the TCR had increased affinity for the specific pepMHC (i.e., for the original antigen that the T cells were specific for). Thus, the wild-type TCR was used as a template for producing mutagenized libraries in one or more of the CDRs, followed by selection of mutants with higher affinity, by binding to the cognate peptide-MHC n. It is well known in the art that such in vitro, directed evolution, is necessary in order to engineer affinities that are more than just a few fold above the wild type affinity.

] Yeast display allows for the protein of interest to be expressed on the surface as an Aga2-fusion (Boder and Wittrup (1997) Nat. Biotech., 15, 553-557; Boder and Wittrup (2000) s Enzymol, 328, 430-44). This system has been used successfully in the engineering of higher affinity TCRs, -chain antibodies, fibronectin, and other proteins. In the yeast y system, the TCR has been yed as a stabilized single-chain protein, in VB-linker-Va or Va-linker-VB forms (Aggen et al. (2011) Protein Engineering, Design, & Selection, 24, 361-72; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387-92; Kieke et al. (1999) Proc Natl Acad Sci U S A, 96, 5651-6; Richman et al. (2009) Mol l, 46, 902-16; Weber et al. (2005) Proc Natl Acad Sci U S A, 102, 19033-8), or as a two-chain heterodimer (Aggen et al. (2011) Protein Engineering, Design, & Selection, 24, 361—72; Richman et al. (2009) Mol Immunol, 46, 902-16). Two mouse TCRs have been engineered for higher affinity using this system: 2C (MHC class-l restricted) and 3.L2 (MHC class-ll restricted) (Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387—92; Weber et al. (2005) Proc Natl Acad Sci U S A, 102, 19033-8). Human TCR single-chain VorVB nts (called sch or scTCR) have also recently been developed by taking advantage of the exceptional stability of the human Vor region called Va2, also known as TCRA12 by IMGT nomenclature (Aggen et al. (2011) Protein Engineering, Design, & Selection, 24, 361-72). In this case, in vitro engineered, high-affinity T cell receptors in a single-chain format were used to isolate human stabilized sch fragments (VB-linker-Va), which could be expressed as stable proteins, both on the surface of yeast and in soluble form from E. coli. The TCRs ed two ized, human sch nts, the A6 sch that is specific for a peptide derived from the human T cell trophic virus Tax protein and the 868 sch that is specific for a peptide derived from the human immunodeficiency virus Gag protein (peptide: SL977-85). Both of these TCRs used the V02 gene (IMGT: TRAV12 family), but they had CDR30i, CDR1B, CDR2[3, and CDR3[3 residues derived from the original T cell clone from which the TCRs were isolated. Thus, the higher affinity mutants of these scTCRs were each derived from their original (parental) TCR against their cognate peptide-MHC antigens.

In a second , phage display, the protein of interest is fused to the N-terminus of a viral coat protein (Scott and Smith (1990) Science, 249, 386-90).

Various TCRs, including those called A6, 868, and 1G4 (MHC class-l cted), have been engineered for higher affinity using this method (Li et al. (2005) Nat Biotechnol, 23, 349—54; Sami et al. (2007) n Eng Des Sel, 20, 397-403; Varela- Rohena et al. (2008) Nat Med, 14, 1390-5). Phage display of these TCRs was enabled by introduction of a non-native disulfide bond between the two C domains in order to promote pairing of the or and B chains. This system thus uses full-length (VuCaNBCB) heterodimeric proteins derived from the al T cell clones for engineering against their cognate peptide-MHC.

A third system that has been ed for the engineering of TCRs is mammalian cell display (Chervin et al. (2008) J l Methods, 339, 175-84; Kessels et al. (2000) Proc Natl Acad Sci U S A, 97, 14578—83). This system uses a retroviral vector to introduce the TCR d and B-chains into a TCR-negative T cell hybridoma. In one study (Kessels et al. (2000) Proc Natl Acad Sci U S A, 97, 14578- 83), the selected mutant TCR was shown to bind to a peptide that was structurally very similar to the cognate peptide (ASNENMDAM versus ASNENMETM; SEQ ID NOs:23 and 24, respectively). In the other study, the affinity of the mutant TCR was shown to be increased for the e pepMHC (Chervin et al. (2008) J Immunol Methods, 339, 175-84). It has been shown in many studies that such higher affinity TCRs also exhibit higher affinities against urally similar variants of the cognate peptide (e.g.,(HolIer et al. (2003) Nat Immunol, 4, 55-62)). In the mammalian cell y system, introduced TCRs were expressed on the surface in its native conformation, in complex with CD3 subunits, ng for a fully functional T cell (signaling competent). Full-length, dimeric TCRs in their native host were thus engineered using this method.

High—Affinity TCRs that Bind to WT1/HLA-A2 The present invention provides for a wild type TCR and various highaffinity TCRs against the well-known cancer antigen WT1/HLA-A2. In certain embodiments, the ered TCRs can be used in soluble form for targeted delivery in vivo, or as recombinantly expressed by T cells in an adoptive er method or treatment. In a ular embodiment, a single-chain VaVB form of the TCR ) scaffold can be prepared and used with a payload such as a cytokine, toxin, radioisotope, chemotherapeutic agent, or drug (similar to antibody—drug conjugates) to deliver the effector molecule to the location where the TCR binds (e.g., tumor). The TCR can also be used in cell therapies, such as adoptive transfer of CD4+ T cells, CD8+ T cells, and/or natural killer (NK) cells, to mediate a response against cancer cells that express WT1. The scTCR scaffolds provided herein can also be used for sis of, e.g., malignant or viral-infected cells through identification of, e.g., neoplastic or viral-associated urface antigens by covalent linkage, for example through amine-reactive or dryl-reactive amino acid side chains of the TCR, to a detectable group, such as a radioisotope or fluorescent moiety.

In one embodiment, the scTCR proteins described herein are yable on the surface of yeast, phage, or mammalian cells and can be used to engineer TCRs with even higher affinity to the WT1 antigen. In one embodiment, the scTCR ns bed herein can be expressed in a prokaryotic cell, such as Escherichia coli, Aspergil/us niger, Aspergi/lus ficuum, Aspergi/lus awamori, Aspergillus Oiyzae, Trichoderma reesei, Mucor miehei, Kluyveromyces lactis, Pichia pastoris, romyces cerevisiae, Bacillus subti/is or Bacillus lichen/formis, insect cells (e.g., hila melanogaster), mammalian cells including cell lines such as Chinese hamster ovary cell lines (CHO), or plant species (e.g., canola, soybean, corn, , barley, rye, wheat) for example, or other art-known protein expression sources and produced in large quantities. The TCR can also be used, for e and by way of example only, to detect the specific peptide/MHC on the surface of a cell. In one embodiment, the scTCR genes disclosed can be linked by use of suitable peptide sequences, encoded within the DNA construct, to the genes for signaling domains and introduced into T cells that can eliminate the targeted cells. These constructs have been termed ic antigen receptors (CARs), which are now widely used in the field, including the use of CARs that contain a scTCR.

In the single-chain VaVB TCR proteins provided, the variable alpha and variable beta chains are connected using any suitable peptide linker, including those known in the art such as with antibody single—chain Fv linkages (Bird et al. (1988) Science, 242, 423-426; Holliger et al. (1993) Proc Natl Acad Sci U S A, 90, 6444-8; Hoogenboom (2005) Nat Biotechnol, 23, 1105-16; Turner et al. (1997) J Immunol Methods, 205, 43-54). In one embodiment, a soluble human single-chain TCR having the structure: Vd-L-VB or d, wherein L is a linker peptide that links V8 with Va, VB is a TCR variable [3 region, and Va is a TCR variable (1 region is provided.

In one embodiment, the VBVa TCR is called WT1 D13.1.1 where VB is a TCR variable [3 region of group 3, and Vd2 is a TCR le or region of group 2 (Utz, U., et al., 1996)(Aggen, D.A., et al., 2011).

In one embodiment, the linker peptide contains more than 5 lysine residues. In one embodiment, the linker peptide contains between 5 and 30 amino acids. In one embodiment, the linker peptide has an amino acid sequence of GSADDAKKDAAKKDGKS (SEQ ID NO:8). In one embodiment, the sc VBVOL TCR provided does not contain a constant region. When the terminology sc VBVQ TCR is used herein, it is understood that sc VBVo TCR is also ed as the terminology is understood and used in the art. Thus, the VB and Va chains can be connected to each other in any configuration through the .

In an aspect of the disclosure, the VBVOL TCR of the disclosure binds specifically to a ligand with an equilibrium binding constant KB of between about 10'6 M and 10'12 M. In one embodiment of this aspect of the disclosure, the ligand is a peptide/MHC ligand. In one embodiment, the VBVa TCR of the disclosure has enhanced affinity toward a ligand compared to the affinities of normal, wild type TCRs. ically Active Groups ] Also provided are VBVa TCR proteins as described herein which includes a biologically active group. As used herein, “biologically active group” is a group that causes a measurable or detectable effect in a biological . In one embodiment, the biologically active group is selected from: an anti-tumor agent such as, but not limited to, angiogenesis inhibitors, enzyme inhibitors, ubule inhibitors, DNA intercalators or cross-linkers, DNA synthesis inhibitors; a ne such as, but not limited to |L-2, lL-15, , |L-12, TNF-0i, IFN-y or LT-0i (Schrama et al. (2006) Nat Rev Drug Discov, 5, ; Wong et al. (2011) Protein Eng Des Sel, 24, 373- 83); an anti-inflammatory group such as, but not limited to, TGF-B, |L-37, |L-10 (Nold et al. (2010) Nat Immunol, 11, 1014-22; Stone et al. (2012) Protein Engineering), a radioisotope such as, but not limited to, 90v or 131i (Reichert and Valge—Archer (2007) Nat Rev Drug Discov, 6, 349-56); a toxin such as, but not limited to, Pseudomonas exotoxin A, diphtheria toxin, or the A chain of ricin (Pastan et al. (2006) Nat Rev Cancer, 6, 559-65; Schrama et al. (2006) Nat Rev Drug Discov, 5, ); a drug, or an antibody such as a single-chain Fv.

In one embodiment of this aspect of the disclosure, the biologically active group is a cytotoxic molecule, mes referred to as a drug (e.g., in the term “antibody drug conjugate”). As used herein, oxic” means toxic to cells.

Examples of cytotoxic les include, but are not limited to, doxorubicin, methotrexate, mitomycin, 5-fluorouracil, duocarmycin, atins, maytansines, calicheamicins and analogs of the above molecules (Jarvis (2012) Chemical and Engineering News, 90, 12-18; Litvak-Greenfeld and Benhar (2012) Adv Drug Deliv Rev; Ricart and Tolcher (2007) Nat Clin Pract Oncol, 4, 245-55). Cytotoxic molecules do not need to cause complete cell death, but rather, a able or detectable inhibition of growth or decrease in cell activity.

In one embodiment, a TCR described herein is linked to an enzyme capable of converting a prodrug into a drug. This is useful, for example, by allowing the active form of the drug to be created at the location ed by the TCR (e.g., at the site of a tumor).

In one embodiment, the biologically active group is bound to the single— chain TCR through a linker, which may be accomplished through standard chemical reactions such as with free amine groups or dryl groups of the TCR.

In another embodiment, the TCR is attached to a single-chain antibody fragment (scFv) to generate a ific agent. Bispecific antibodies that contain one scFv against a tumor antigen, and one against the CD3 molecule of the T cell have now been used successfully in the clinic (Bargou et al. (2008) Science, 321, 974-7).

In addition, a bispecific agent ning a TCR and a scFv against CD3 has also been reported (Liddy et al. (2012) Nat Med, 18, 980-7).

Also provided is a single-chain VBVoc TCR as described herein which includes a detectable group. In one embodiment, the detectable group is one that can be detected by spectroscopic or enzyme-based methods. In one embodiment, the detectable group is a scent group, such as, but not limited to fluorescein, R- phycoerythrin (PE), PE-Cy5, PE-Cy7, Texas red, or allophycocyanin (APC); a radiolabeled group such as, but not d to, 125i, 32P, 99mTc; an absorbing group, or an enzyme with ties that generate detectable products such as, but not limited to, horseradish dase, or alkaline phosphatase.

As known in the art, a biologically active group, detectable group or other group ed to the TCR can be attached using a flexible peptide linker or by chemical conjugation, and can be covalently or noncovalently attached to the TCR.

] Also provided herein is a human TCR for use in a method of treating or preventing cancer in a mammal, comprising administering an effective amount of a modified TCR linked to a eutically effective molecule to a mammal. In a particular embodiment, the mammal is human. In another embodiment, the mammal is a companion animal (e.g., a dog, cat, , rodent, horse) or a livestock animal (e.g., a cow, horse, pig).

Also provided is an isolated single-chain TCR (scTCR) as described herein, and a method for producing the single-chain TCR in E. coli. Also provided is a pharmaceutical composition comprising a scTCR as described herein and a pharmaceutically acceptable r.

Also provided is the sc VaVB TCRs described herein which have been linked to ing domains that yields an active TCR on the surface of a T cell. In one embodiment, this scTCR can be used in a method of treating cancer in a mammal, comprising: cloning the TCR into a vector, introducing the vector into T cells of a patient, and adoptive erring of the T cells back into a patient. ed TCR Polypeptides and Polynucleotides The disclosure contemplates a DNA vector that includes at least one DNA segment encoding a single—chain T cell receptor (scTCR).

Those of skill in the art, through standard mutagenesis techniques, conjunction with the assays described herein, can obtain altered TCR sequences and test them for particular binding ty andlor specificity. Useful mutagenesis techniques known in the art include, without limitation, de novo gene synthesis, oligonucleotide-directed mutagenesis, -specific nesis, linker-scanning mutagenesis, and site-directed mutagenesis by PCR (see e.g., Sambrook et al. (1989) and Ausubel et al. (1999)).

In obtaining modified TCR coding sequences, those of ordinary skill in the art will recognize that rived proteins may be modified by certain amino acid substitutions, additions, deletions, and post-translational modifications, without loss or reduction of ical activity. In particular, it is well known that conservative amino acid tutions, that is, substitution of one amino acid for another amino acid of similar size, charge, polarity and conformation, are unlikely to significantly alter protein function. The 20 standard amino acids that are the constituents of ns can be broadly categorized into four groups of conservative amino acids as follows: the nonpolar (hydrophobic) group includes e, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine; the polar rged, neutral) group includes asparagine, cysteine, glutamine, glycine, serine, threonine and tyrosine; the positively charged (basic) group contains arginine, ine and lysine; and the negatively charged (acidic) group contains aspartic acid and glutamic acid. Substitution in a protein of one amino acid for r within the same group is unlikely to have an adverse effect on the biological ty of the n.

] In one embodiment, a scTCR of the disclosure may contain onal mutations in any region or regions of the variable domain that results in a stabilized protein. In one embodiment, one or more additional ons is in one or more of CDR1, CDR2, HV4, CDR3, FR2, and FR3. The regions used for mutagenesis can be determined by directed evolution, where crystal structures or molecular models are used to generate regions of the TCR which interact with the ligand of interest (antigen, for example). In other examples, the variable region can be reshaped, by adding or deleting amino acids to engineer a desired interaction between the scTCR and the ligand.

] Polypeptides of the invention include modified TCRs, and antigen binding fragments thereof (e.g., scTCR), and chimeric antigen receptors (CARS). The terms "polypeptide protein" and "peptide" and "glycoprotein" are used interchangeably and mean a polymer of amino acids not limited to any particular length. The term does not exclude modifications such as myristylation, sulfation, glycosylation, phosphorylation and addition or deletion of signal sequences. The terms "polypeptide" or "protein" means one or more chains of amino acids, wherein each chain comprises amino acids ntly linked by peptide bonds, and wherein said ptide or protein can comprise a ity of chains non-covalently and/or covalently linked together by peptide bonds, having the sequence of native proteins, that is, proteins produced by naturally-occurring and specifically non-recombinant cells, or genetically-engineered or recombinant cells, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence.

The terms "polypeptide" and "protein" specifically encompass the modified TCRs, or antigen-binding fragments thereof, of the present disclosure, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of a modified TCR, or antigen g fragment thereof. Thus, a "polypeptide" or a "protein" can comprise one (termed "a r") or a plurality (termed “a multimer") of amino acid chains.

The term “isolated n" referred to herein means that a subject protein (1) is free of at least some other proteins with which it would typically be found in nature, (2) is essentially free of other proteins from the same source, e.g., from the same species, (3) is expressed by a cell from a ent species, (4) has been ted from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is not associated (by covalent or noncovalent interaction) with portions of a protein with which the "isolated protein" is associated in nature, (6) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (7) does not occur in nature. Such an isolated protein can be encoded by genomic DNA, cDNA, mRNA or other RNA, of may be of synthetic origin, or any combination thereof. In certain ments, the isolated protein is substantially free from proteins or ptides or other contaminants that are found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research or otherwise).

In particular embodiments, a subject modified TCR may have: a) a TCR alpha chain variable region having an amino acid sequence that is at least 80% identical, at least 85% identical, at least 90%, at least 95% or at least 98% or 99% identical, to the alpha chain le region of a modified TCR described herein; and b) a beta chain variable region having an amino acid sequence that is at least 80% identical, at least 85%, at least 90%, at least 95% or at least 98% or 99% identical, to the beta chain variable region of a modified TCR described herein.

In particular embodiments, the modified TCR may comprise: a) a TCR alpha chain variable region comprising: i. a CDR1 region that is identical in amino acid sequence to the alpha chain CDR1 region of a selected TCR described herein; ii. a CDR2 region that is identical in amino acid sequence to the alpha chain CDR2 region of the selected TCR; and iii. a CDR3 region that is identical in amino acid sequence to the alpha chain CDR3 region of the ed TCR; and b) a beta chain variable region sing: i. a CDR1 region that is identical in amino acid sequence to the beta chain CDR1 region of the selected TCR; ii. a CDR2 region that is identical in amino acid ce to the beta chain CDR2 region of the selected TCR; and iii. a CDR3 region that is identical in amino acid sequence to the beta chain CDR3 region of the selected TCR; wherein the TCR specifically binds a the WT1 antigen. In a further embodiment, the modified TCR, or antigen-binding fragment thereof, is a variant modified TCR wherein the variant comprises an alpha chain and a beta chain cal to the ed modified TCR except for up to 8, 9, 10, 11, 12, 13, 14, 15, or more amino acid tutions in the CDR regions of the V alpha and V beta regions. In this regard, there may be 1, 2, 3, 4, 5, 6, 7, 8, or in certain embodiments, 9, 10, 11, 12, 13, 14, 15 more amino acid substitutions in the CDR regions of the selected variant modified TCR. Substitutions may be in CDRs either in the V alpha and/or the V beta regions. (See e.g., Muller, 1998, Structure 6:1153- 1167).

In one embodiment, a polynucleotide encoding a modified TCR, or an antigen-binding fragment thereof, is provided. In other related embodiments, the polynucleotide may be a variant of a cleotide encoding the modified TCR.

Polynucleotide variants may have substantial identity to a polynucleotide sequence encoding a modified TCR described herein. For example, a polynucleotide may be a polynucleotide comprising at least 70% sequence ty, preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or , sequence identity compared to a reference polynucleotide sequence such as a sequence ng an TCR described herein, using the methods described herein, (e.g., BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

Typically, cleotide variants will contain one or more substitutions, additions, deletions and/or insertions, ably such that the binding affinity of the TCR encoded by the variant polynucleotide is not ntially diminished relative to an TCR encoded by a polynucleotide sequence specifically set forth herein.

When comparing polynucleotide sequences, two sequences are said to be ical” if the sequence of nucleotides in the two sequences is the same when aligned for m correspondence, as bed below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to fy and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

] Optimal ent of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of ormatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, MO. (1978) A model of evolutionary change in proteins — Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345- 358; Hein J., Unified Approach to Alignment and enes, pp. 626-645 (1990); Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M., CABIOS 5:151—153 (1989); Myers, E.W. and Muller W., CABIOS 7 (1988); Robinson, E.D., Comb. Theor 11:105 (1971); Santou, N.

Nes, M., Mol. Biol. Evol. 4:406-425 (1987); Sneath, P.H.A. and Sokal, R.R., Numerical Taxonomy — the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA (1973); Wilbur, W.J. and Lipman, D.J., Proc.

Natl. Acad., Sci. USA 80:726-730 (1983).

Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman, Add. APL. Math 2:482 (1981), by the identity alignment thm of Needleman and Wunsch, J. Mol.

Biol. 482443 (1970), by the search for similarity methods of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics re Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by tion.

One preferred example of algorithms that are suitable for determining percent ce identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nucl. Acids Res. 25:3389-3402 (1977), and Altschul et al., J. Mol. Biol. 3-410 (1990), respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine t sequence identity among two or more the cleotides.

Software for performing BLAST analyses is publicly ble through the National Center for hnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). ion of the word hits in each direction are halted when: the tive alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.

The BLAST algorithm parameters W, T and X ine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a ngth (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

In certain embodiments, the “percentage of sequence identity” is determined by comparing two optimally d sequences over a window of comparison of at least 20 positions, wherein the portion of the cleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, y 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases occurs in both ces to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the nce sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode an TCR as described herein. Some of these polynucleotides bear minimal sequence identity to the nucleotide sequence of the native or original polynucleotide sequence that encode modified TCRs that bind to, e.g., the same antigen.

Nonetheless, polynucleotides that vary due to differences in codon usage are sly contemplated by the present disclosure. In certain embodiments, ces that have been codon-optimized for ian expression are specifically contemplated.

Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various tion techniques are those known and ly employed by those skilled in the art. A number of standard techniques are described in Sambrook et al. (1989) Molecular Cloning, Second Edition, Cold Spring Harbor Laboratory, Plainview, New York; Maniatis et al. (1982) Molecular Cloning, Cold Spring Harbor Laboratory, Plainview, New York; Wu (ed.) (1993) Meth. Enzymol. 218, Part I; Wu (ed.) (1979) Meth Enzymol. 68; Wu et al. (eds.) (1983) Meth. Enzymol. 100 and 101; an and Moldave (eds.) Meth.

Enzymol. 65; Miller (ed.) (1972) Experiments in Molecular cs, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Old and Primrose (1981) Principles of Gene Manipulation, University of California Press, Berkeley; Schleif and Wensink (1982) Practical Methods in Molecular Biology; Glover (ed.) (1985) DNA Cloning Vol. I and II, IRL Press, Oxford, UK; Hames and Higgins (eds.) (1985) Nucleic Acid Hybridization, IRL Press, , UK; and Setlow and Hollaender (1979) Genetic Engineering: ples and Methods, Vols. 1-4, Plenum Press, New York. Abbreviations and nomenclature, where employed, are deemed standard in the field and commonly used in professional journals such as those cited herein.

Homology between nucleotide sequences can be determined by DNA hybridization analysis, wherein the stability of the double-stranded DNA hybrid is dependent on the extent of base pairing that occurs. Conditions of high temperature and/or low salt content reduce the stability of the hybrid, and can be varied to prevent annealing of sequences having less than a ed degree of homology.

For instance, for sequences with about 55% G - C content, hybridization and wash conditions of 40 - 50°C, 6 X SSC (sodium chloride/sodium citrate buffer) and 0.1% SDS (sodium dodecyl e) indicate about 60 — 70% homology, hybridization and wash conditions of 50 - 65°C, 1 X SSC and 0.1% SDS indicate about 82 - 97% homology, and hybridization and wash conditions of 52°C, 0.1 X SSC and 0.1% SDS indicate about 99 — 100% homology. A wide range of computer programs for comparing nucleotide and amino acid sequences (and measuring the degree of homology) are also available, and a list providing sources of both commercially ble and free software is found in l et al. . Readily available sequence comparison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool ) (Altschul et al., 1997) and ClustalW programs. BLAST is available on the Internet at ncbi.n|m.nih.gov and a version of ClustalW is available at www2.ebi.ac.uk.

Industrial strains of microorganisms (e.g., Aspergillus niger, Aspergillus ficuum, Aspergillus awamori, Aspergillus , Trichoderma reesei, Mucor miehei, romyces lactis, Pichia pastoris, Saccharomyces cerevisiae, Escherichia coli, Bacillus subtilis or Bacillus licheniformis), insect (Drosophila), mammalian (e.g.,Chinese hamster ovary cell lines, CHO), or plant species (e.g., , soybean, corn, potato, barley, rye, wheat) may be used as host cells for the recombinant production of the TCR proteins. In certain embodiments, the first step in the heterologous expression of a high affinity TCR protein or soluble protein, an expression construct is assembled to include the TCR or soluble TCR coding ce and l sequences such as promoters, enhancers and ators.

Other sequences such as signal sequences and selectable s may also be included. To achieve extracellular expression of the TCR, the expression construct may include a secretory signal ce. In embodiments, the signal sequence is not included on the expression construct if cytoplasmic expression is desired. In embodiments, the promoter and signal sequence are functional in the host cell and provide for expression and secretion of the TCR or soluble TCR protein.

Transcriptional terminators may be included to ensure efficient transcription.

Ancillary sequences enhancing expression or protein purification may also be included in the expression construct.

Various promoters (transcriptional initiation regulatory region) may be used according to the disclosure. The selection of the appropriate promoter may be dependent upon the proposed expression host. Promoters from heterologous sources may be used as long as they are onal in the chosen host.

Promoter selection is also dependent upon the desired efficiency and level of peptide or protein production. Inducible promoters such as tac are often ed in order to dramatically increase the level of protein sion in E. coli.

Overexpression of proteins may be harmful to the host cells. Consequently, host cell growth may be limited. The use of inducible er s allows the host cells to be ated to acceptable densities prior to induction of gene expression, thereby facilitating higher product yields.

] Various signal sequences may be used according to the disclosure. A signal sequence which is homologous to the TCR coding sequence may be used.

Alternatively, a signal sequence which has been selected or designed for efficient secretion and processing in the expression host may also be used. For example, suitable signal sequence/host cell pairs include the B. subtilis sacB signal sequence for secretion in B. subtilis, and the Saccharomyces cerevisiae o-mating factor or P. pastoris acid phosphatase phol signal sequences for P. pastoris secretion. The signal sequence may be joined directly through the sequence encoding the signal peptidase cleavage site to the protein coding sequence, or through a short nucleotide bridge consisting of usually fewer than ten codons, where the bridge ensures correct reading frame of the downstream TCR sequence. ts for enhancing ription and translation have been identified for eukaryotic protein expression systems. For example, positioning the cauliflower mosaic virus (CaMV) promoter 1000 bp on either side of a heterologous er may elevate transcriptional levels by 10- to 400-fold in plant cells. The expression construct should also include the riate translational initiation sequences.

Modification of the sion construct to include a Kozak consensus sequence for proper translational initiation may increase the level of translation by 10 fold.

A selective marker is often employed, which may be part of the expression construct or separate from it (e.g., carried by the expression vector), so that the marker may integrate at a site different from the gene of interest. Examples include markers that confer ance to antibiotics (e.g., bla confers resistance to ampicillin for E. coli host cells, nptll confers kanamycin resistance to a wide variety of prokaryotic and eukaryotic cells) or that permit the host to grow on minimal medium (e.g., HIS4 enables P. pastoris or His- S. cerevisiae to grow in the absence of histidine). The selectable marker has its own transcriptional and translational initiation and termination regulatory regions to allow for ndent expression of the marker. If otic resistance is employed as a , the tration of the antibiotic for selection will vary depending upon the antibiotic, generally ranging from to 600 ug of the otic/mL of medium.

The sion construct is assembled by ing known recombinant DNA techniques (Sambrook et al., 1989; Ausubel et al., 1999). Restriction enzyme digestion and ligation are the basic steps employed to join two fragments of DNA.

The ends of the DNA fragment may e modification prior to ligation, and this may be accomplished by filling in overhangs, deleting terminal portions of the fragment(s) with nucleases (e.g., Exolll), site directed nesis, or by adding new base pairs by PCR. Polylinkers and adaptors may be employed to facilitate joining of selected fragments. The expression construct is typically assembled in stages employing rounds of restriction, ligation, and transformation of E. coli.

Numerous cloning vectors suitable for construction of the sion construct are known in the art (AZAP and pBLUESCRIPT SK-1, Stratagene, LaJoIla, CA; pET, Novagen Inc., Madison, WI - cited in Ausubel et al., 1999) and the particular choice is not critical to the disclosure. The selection of cloning vector will be influenced by the gene transfer system selected for introduction of the expression construct into the host cell. At the end of each stage, the ing construct may be analyzed by restriction, DNA sequence, hybridization and PCR analyses.

The expression construct may be transformed into the host as the cloning vector construct, either linear or ar, or may be removed from the cloning vector and used as is or introduced onto a delivery vector. The delivery vector facilitates the introduction and maintenance of the expression construct in the selected host cell type. The expression construct is introduced into the host cells by any of a number of known gene transfer systems (e.g., l ence, chemically mediated ormation, protoplast transformation, electroporation, biolistic transformation, transfection, or conjugation) (Ausubel et al., 1999; Sambrook et al., 1989). The gene transfer system selected depends upon the host cells and vector systems used.

For instance, the expression construct can be introduced into S. siae cells by protoplast transformation or electroporation. Electroporation of S. cerevisiae is readily accomplished, and yields ormation efficiencies comparable to spheroplast transformation.

Monoclonal or onal antibodies, preferably monoclonal, specifically reacting with a TCR protein at a site other than the ligand binding site may be made by methods known in the art, and many are commercially available. See, e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories; Goding (1986) onal Antibodies: Principles and Practice, 2d ed., Academic Press, New York; and Ausubel et al. (1999) Current ols in Molecular Biology, John Wiley & Sons, Inc, New York.

] TCRs in cell-bound or e form which are specific for a particular target ligand are useful, for example, as diagnostic probes for screening biological samples (such as cells, tissue samples, biopsy material, bodily fluids and the like) or for detecting the presence of the target ligand in a test . Frequently, the TCRs are labeled by joining, either covalently or noncovalently, a nce which provides a detectable signal. le labels include but are not limited to uclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent , magnetic particles and the like. Additionally the TCR can be coupled to a ligand for a second binding molecule: for example, the TCR can be biotinylated. Detection of the TCR bound to a target cell or molecule can then be effected by binding of a detectable streptavidin (a streptavidin to which a fluorescent, radioactive, chemiluminescent, or other detectable molecule is ed or to which an enzyme for which there is a chromophoric substrate ble). United States Patents describing the use of such labels and/or toxic compounds to be covalently bound to the scTCR include but are not limited to Nos. 3,817,837; 3,850,752; 3,927,193; 3,939,350; 3,996,345; 437; 4,275,149; 4,331,647; 4,348,376; 4,361,544; 4,468,457; 4,444,744; 4,640,561; 4,366,241; RE 35,500; 5,299,253; ,101,827; 5,059,413.

Labeled TCRs can be detected using a monitoring device or method appropriate to the label used. Fluorescence microscopy or fluorescence activated cell sorting can be used where the label is a fluorescent moiety, and where the label is a radionuclide, gamma counting, autoradiography or liquid scintillation counting, for example, can be used with the proviso that the method is appropriate to the sample being analyzed and the radionuclide used. In addition, there can be secondary detection molecules or particle employed where there is a detectable molecule or particle which recognized the portion of the TCR which is not part of the binding site for the target ligand in the absence of a MHC component as noted herein. The art knows useful compounds for diagnostic imaging in situ; see, e.g., U.S. Patent No. 827; 5,059,413. Radionuclides useful for therapy and/or imaging in vivo include 111indium, 97Rubidium, 125iooiine, 131Iodine, 123Iodine, 67Gallium, 99Technetium. Toxins include diphtheria toxin, ricin and castor bean toxin, among others, with the proviso that once the TCR-toxin complex is bound to the cell, the toxic moiety is alized so that it can exert its cytotoxic effect. lmmunotoxin technology is well known to the art, and suitable toxic molecules include, without limitation, chemotherapeutic drugs such as vindesine, antifolates, e.g., methotrexate, cisplatin, cin, anthrocyclines such as ycin, daunorubicin or adriamycin, and cytotoxic proteins such as me inactivating ns (e.g., diphtheria toxin, pokeweed antiviral protein, abrin, ricin, pseudomonas exotoxin A or their recombinant derivatives. See, lly, e.g., Olsnes and Pihl (1982) Pharmac.

Ther. 25:355-381 and Monoclonal Antibodies for Cancer Detection and y, Eds. Baldwin and Byers, pp. 159-179, Academic Press, 1985.

] The general structure of TCR molecules and methods of making and using, including binding to a peptide:Major Histocompatibility Complex have been disclosed. See, for example PCT/U898/04274; PCT/U898/20263; W099/60120. ceutical Compositions and Therapeutic Agents TCRs specific for a particular target ligand are useful in treating animals and mammals, including humans believed to be suffering from a disease associated with the particular antigen, e.g., a neoplastic disease or disorder, such as cancer.

Examples of types of cancers that may be treated according to the methods described herein include, but are not limited to, Wilm’s tumour, r cancer, breast cancer, colon cancer, colorectal cancer, esophageal carcinomas, gastric cancer, hepatocellular carcinoma, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, neuroblastoma, non-small cell lung carcinoma, oral cancer, osteosarcoma, ovarian cancer, atic cancer, prostate cancer, renal cancer, skin cancer, small cell lung carcinoma, and testicular cancer.

Therapeutic products can be made using the materials shown herein.

Effective amounts of therapeutic ts are the minimum dose that produces a measurable effect in a subject. Therapeutic products are easily prepared by one of ordinary skill in the art. In one embodiment, a scTCR of the disclosure is administered directly to a patient. In one embodiment, a scTCR of the disclosure is linked to PEG or to immunoglobulin constant regions, as known in the art. This embodiment lengthens the serum clearance. In one embodiment, the scTCR is linked to a chemotherapeutic agent or drug in order to r the drug to a target cell such as a cancer cell. In one embodiment, the scTCR is linked to a biologic effector le such as a cytokine (Tayal and Kalra (2008) EurJ Pharmacol, 579, 1-12). In one embodiment, the scTCR is linked to a cytokine with umor activity, such as lL-2, lL-12, or TNFd (Wong et al. (2011) n Eng Des Sel, 24, 373—83). In one embodiment, the scTCR is linked to an -inhibitory cytokine, such as lL—10 or lL-13 (Stone et al. (2012) Protein Engineering). In one ment, the scTCR is linked to another n g molecule to form a bispecific agent (Miller et al. (2010) Protein Eng Des Sel, 23, 549-57; Thakur and Lum (2010) Curr Opin Mol Ther, 12, 340-9). In one embodiment, the bispecific molecule is comprised of a scTCR linked to a single chain Fv, such as an anti-CD3 ((Bargou et al. (2008) Science, 321, 974—7; Liddy et al. (2012) Nat Med, 18, 980-7), to crosslink T cells and diseased cells. In one embodiment, the scTCR is linked to TCR signaling domains, such as CD3, to form a chimeric antigen receptor ((Porter et al. (2011) N Engl J Med, 365, 725-33; Sadelain et al. (2009) Curr Opin Immunol, 21, 215-23; Stroncek et al. (2012) J Transl Med, 10, 48). These methods and other methods of administering, such as enously, are known in the art. Useful dosages can be determined by one of ry skill in the art.

The scTCR itions can be formulated by any of the means known in the art. They can be typically prepared as injectables, especially for intravenous, intraperitoneal or synovial administration (with the route determined by the particular e) or as formulations for asal or oral administration, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection or other administration may also be prepared. The preparation may also, for example, be emulsified, or the protein(s)/peptide(s) encapsulated in liposomes.

] The active ingredients are often mixed with optional pharmaceutical additives such as excipients or carriers which are pharmaceutically acceptable and compatible with the active ingredient. Suitable ents include but are not d to water, saline, dextrose, glycerol, ethanol, or the like and ations f.

The concentration of the scTCR in injectable, aerosol or nasal formulations is usually in the range of 0.05 to 5 mg/ml. The selection of the particular effective dosages is known and performed without undue experimentation by one of ordinary skill in the art. Similar dosages can be administered to other mucosal surfaces.

In addition, if desired, vaccines that could e a scTCR may contain minor amounts of pharmaceutical ves such as auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide; N—acetyl-muramyl-L-threonyl- Disoglutamine (thr-MDP); N-acetyl-nor—muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N—acetylmuramyl—L-alanyl—D-isoglutaminyl-L- alanine(1'-2'-dipalmitoyl-sn-glycero-3hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE); and RIBI, which ns three components extracted from bacteria: osphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween® 80 emulsion. Such additional formulations and modes of administration as are known in the art may also be used.

The scTCRs of the present disclosure and/or binding fragments having primary structure similar (more than 90% identity) to the TCR variable regions and which maintain the high affinity for the target ligand may be formulated into vaccines as neutral or salt forms. Pharmaceutically acceptable salts include but are not limited to the acid addition salts (formed with free amino groups of the peptide) which are formed with inorganic acids, e.g., hydrochloric acid or phosphoric acids; and c acids, e.g., acetic, oxalic, tartaric, or maleic acid. Salts formed with the free carboxyl groups may also be derived from inorganic bases, e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides, and c bases, e.g., isopropylamine, trimethylamine, 2—ethylamino-ethanol, histidine, and procaine. ] scTCRs for therapeutic use are administered in a manner compatible with the dosage formulation, and in such amount and manner as are lactically and/or therapeutically effective, according to what is known to the art. The quantity to be stered, which is generally in the range of about 100 to 20,000 ug of n per dose, more generally in the range of about 1000 to 10,000 ug of protein per dose. Similar compositions can be administered in similar ways using labeled scTCRs for use in imaging, for e, to detect cells to which a target ligand is bound. Precise amounts of the active ingredient required to be administered may depend on the judgment of the physician or veterinarian and may be peculiar to each individual, but such a ination is within the skill of such a practitioner.

The TCR product may be given in a single dose; two dose schedule, for example two to eight weeks apart; or a multiple dose schedule. A multiple dose schedule is one in which a primary course of treatment may include 1 to 10 or more separate doses, ed by other doses administered at subsequent time intervals as ed to maintain and/or reinforce the response.

Every formulation or combination of ents described or exemplified can be used to practice the disclosure, unless othenNise stated. Specific names of nces are intended to be exemplary, as it is known that one of ordinary skill in the art can name the same substances differently. When a compound is described herein such that a particular isomer or omer of the compound is not specified, for example, in a formula or in a chemical name, that description is intended to include each isomers and enantiomer of the compound described individual or in any ation. One of ordinary skill in the art will appreciate that methods, target ligands, biologically active groups, starting materials, and synthetic methods other than those specifically exemplified can be ed in the practice of the disclosure without resort to undue experimentation. All art-known functional equivalents, of any such methods, target ligands, biologically active groups, ng materials, and synthetic methods are intended to be included in this disclosure. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure.

The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see e.g., Fingl et. al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1).

It should be noted that the attending physician would know how to and when to ate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending ian would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose ncy, will also vary according to the age, body weight, and se of the individual patient. A program comparable to that discussed above also may be used in veterinary ne.

Depending on the specific conditions being treated and the targeting method selected, such agents may be formulated and administered systemically or y. Techniques for formulation and administration may be found in Alfonso and Gennaro (1995). Suitable routes may include, for example, oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including uscular, aneous, or intramedullary injections, as well as intrathecal, intravenous, or eritoneal injections.

For injection, the agents of the disclosure may be formulated in s solutions, preferably in logically compatible buffers such as Hanks' solution, Ringer's solution, or logical saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation.

Such penetrants are generally known in the art.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the disclosure into dosages suitable for systemic stration is within the scope of the disclosure. With proper choice of carrier and suitable cturing practice, the compositions of the present disclosure, in particular those formulated as solutions, may be administered parenterally, such as by intravenous injection. Appropriate compounds can be ated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the disclosure to be formulated as s, pills, capsules, liquids, gels, , slurries, suspensions and the like, for oral ingestion by a patient to be treated.

] Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, and then administered as described above. Liposomes are spherical lipid rs with aqueous interiors. All molecules present in an aqueous on at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. onally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the t disclosure include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. ination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

In addition to the active ingredients, these pharmaceutical compositions may n suitable pharmaceutically acceptable carriers comprising excipients and aries which facilitate processing of the active nds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions, including those formulated for delayed release or only to be ed when the pharmaceutical reaches the small or large intestine.

The pharmaceutical itions of the t disclosure may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, ping or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.

Suitable lipophilic ts or vehicles include fatty oils such as sesame oil, or tic fatty acid esters, such as ethyl oleate or triglycerides, or mes.

Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.

Optionally, the suspension may also contain le stabilizers or agents which se the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of es, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, ol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, ypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If d, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium te.

Dragee cores are provided with le coatings. For this purpose, concentrated sugar solutions may be used, which may optionally n gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push—fit capsules can n the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

Methods of Treatment The high affinity TCRs and pharmaceutical itions comprising a high affinity TCR may be used, for e, to treat a patient having a cancer, tumor, malignancy, or stic disease or er. In one embodiment, a method of treating a patient having cancer comprises administering a high affinity TCR described herein. In one embodiment, the high affinity TCR is specific for WT1. In one embodiment, the TCR comprises a VB comprising the amino acid sequence set forth in SEQ ID NO:3. In r ment, the TCR comprises a V0I sing the amino acid sequence set forth in SEQ ID NO:4. In one embodiment, the high affinity TCR is a single chain TCR comprising the amino acid sequence set forth in SEQ ID NO:5. In another embodiment, the high affinity TCR is administered in combination with a therapeutic agent, e.g., a chemotherapeutic agent. In yet another embodiment, the high affinity TCR is conjugated to a biologically active group.

] Another aspect of the invention provides a method for the adoptive transfer of T cells to a patient in need thereof, comprising administering T cells that s either the wild type TCR or a high affinity TCR described herein. In one embodiment, the T cells have been transfected with a polynucleotide that encodes a TCR that is specific for WT1. In one embodiment, the TCR comprises a VB comprising the amino acid sequence set forth in SEQ ID NO:3. In another embodiment, the TCR comprises a Va comprising the amino acid sequence set forth in SEQ ID NO:4. In one embodiment, the high affinity TCR is a single chain TCR comprising the amino acid sequence set forth in SEQ ID NO:5.

EXAMPLES The following es further describe non-limiting examples of the disclosure.

EXAMPLE 1 ENGINEERING TCRs FOR HIGHER AFFINITY FOR E/HLA-A2 ANTIGENS The general strategy used to discover, or te single-chain TCRs for ed affinity and stability is shown in Figure 3. The process involves six steps, as illustrated: 1) Cloning the Va and V8 TCR genes from a T cell clone such as P22 (sequence shown in Figure 1, and the VB comprising the amino acid sequence set forth in SEQ ID NO:1 and the Va comprising the amino acid sequence set forth in SEQ ID NO:2) as a single chain TCR format for display. The V regions recognize the HLA-A2-restricted antigenic peptide WT1 (SEQ ID NO:6) in complex with . In the present invention, the TCR V region genes from clone P22 (e.g. Dossett et al. (2009) Mol Ther. 17(4), 742) were cloned as a single-chain format (VB-linker-Va) and introduced into a yeast display vector for sion on the surface of yeast (Figure 2) tion of an error prone library and FACs or magnetic bead selection for stabilized variants with an anti-V8 antibody. e the single-chain Va and V8 TCRs are often unstable due to loss of the stabilizing constant regions, error—prone mutagenesis libraries are generated to select for izing mutations that allow for stable expression on the surface of yeast, although other display formats including but not limited to phage and mammalian display may be used.

Phage display vectors and cloning have yielded y sizes of 1011, whereas yeast display vectors and homologous recombination steps have yielded library sizes of 101° ((Benatuil et al. (2010) Protein Eng Des Sel, 23, 155-9). Various methods have been used for selection of variants, including affinity-based binding to immobilized ligands (phage display) or magnetic particle ions with antigens (yeast display), or scent activated cell sorting with d-peptide-MHC antigens (yeast display). Utilizing antibodies against the TCR V8 that recognize folded epitopes, fluorescent activated cell sorting (FACS) or magnetic bead selection are used to isolate variants with improved dy binding in the present example. 3) scTCR clones isolated from the selection of the error prone library are assessed for thermal stability and a ize variant is chosen for a template for affinity maturation, and ced. Typically, single-site mutations are identified that contribute to increased surface levels on yeast, and greater stability in solution. 4) The ized scTCR sequences are used as a template for the generation of CDR libraries, usually in the CDR1a, CDR3a, CDR38, although other regions including but not limited to the CDR1B, , CDR2B, and HV4 can also be used. In the t disclosure, yeast displayed variants are selected for improved binding to peptide:MHC, from the CDR libraries, by using magnetic bead selections and/or scence activated cell sorting (FACS), although selections ing other methods ing but not limited to panning with phage display or magnetic ions or FACS with ian display may be used. 5) scTCR clones isolated from the selection of the CDR ies are assessed for ic binding to the peptide:MHC against which they were engineered. Plasmids are rescued from the yeast clones, and sequenced. 6) If further improvements of affinity required, the scTCR clone selected in step 5 can be used as a template for the generation of additional libraries in other loops or regions that did not select mutations such as CDR1(X, CDR30i, CDR3B, although other s including but not limited to the CDR1B, CDRZOL, CDR2B, and HV4 can also be used. Examples of each of these steps are described further below.

EXAMPLE 2 ANALYSIS OF THE HUMAN TCR A6, WHICH USES THE Va2, IN X WITH TAX:HLA.A2 TCRs all adopt a similar lg-fold and docking angle, and TCR recognition of pepMHC is mediated entirely by specific residues on CDR loops a et al. (2009) Nat Immunol, 10, 143-7; Marrack et al. (2008) Annu Rev Immunol, 26, 171-203; Rudolph et al. (2006) Annu Rev Immunol, 24, 419-66)). Although crystal structures for the WT1 TCRs are not available at the time of the present disclosure, the structure of the A6:Tax peptide:HLA-A2 complex (PDB: 1AO7) (Garboczi et al. (1996) Nature, 384, 134-141), which used the same Va2 domain of the WT1 P22 TCR is shown. The side view of the complex showed that the ends of the variable domains that contained the six CDRs docked onto the Tax:HLA.A2 molecule, with the central region of the binding site positioned over the peptide Tax (Figure 2A).

The crystal structure does not include the constant region or, although the constant regions help stabilize the full length construct. Stabilizing mutations selected in step 2 described above are often selected in framework regions, such as the VOJVB interface or where the junctions of the Cor/Von or CB/VB interface occurs in the full length TCR.

The top down view of the TaX:HLA-A2 complex, with the TCR “removed”, except for the six CDR loops is shown (Figure 28). This view shows that the TCR adopts a diagonal position over the peptide-MHC, a finding which has now been observed for all TCRzpeptide-MHC structures. In this orientation, the two CDR3 loops are positioned over the peptide, while there are s residues from CDR1 and CDR2 loops that interact predominantly with the helices of the MHC molecule.

For purposes of ty maturation in steps 4 and 6, these loops are often the ed for the generation of affinity maturations ies, although other regions may be used.

EXAMPLE 3 YEAST DISPLAY OF WT1 TCRS In order to perform selections for improved stability (step 2) or improved affinity (step 5), it is ary to use a display system in which a library of TCR mutants can be screened for binding to an antibody which recognizes a conformation epitope or a peptide:MHC ligand, respectively. Three display systems have been used for engineering TCRs for higher affinity, and could be used for this process: yeast display, phage display, and T cell (mammalian cell) display. Alternative y methods, such as ribosome, RNA, DNA, and CIS display, may also be suitable for this process. In all of these cases, the wild type TCR with low ty for the antigen was cloned into the , and used as a template for engineering TCRs with enhanced stability and affinity against the peptidezMHC ligand. Any of these systems could be applied to the approach described here, in which a single TCR is used as a template for libraries and the selection of TCRs with enhanced binding properties.

] In the present example, yeast display was used as the platform (Figure 4).

The WT1 TCR was used as the template for stabilizing mutations via error prone mutagenesis, and stabilized clones ed from the selections were used as templates for affinity maturation.

EXAMPLE 4 ERROR-PRONE Y CONSTRUCTION AND SELECTION OF A STABILIZED WT1 TCR, WT1- ] The WT1 error-prone y was generated as previously described (Richman et al. (2009) Methods Mol Biol 504, 323-350) utilizing the WT1-reactive cell line called P22 as a template. The human WT1 prone scTCR library was thus introduced into the yeast display vector by combining the linearized pCT302 vector, WT1 error-prone PCR product, and competent EBY100 yeast cells. The resultant library contained about 2.3 X 107 independent clones, was judged by plating limiting dilution aliquots of yeast after electroporation. The library was selected for binding to two antibodies that recognize human hV[33, anti-hV[33.1 FITC lgG (Thermo Scientific) and anti-hVBB FITC lgM (Beckman Coulter), via FACS according to Table 1.

Table 1. Sorting ions Thermo Scientific hVB3.1 FITC (1 :10); AlexaFluor® 647 Goat anti—mouse lgG (1:100) Beckman Coulter hVB3 FITC lgM (1 :10); Goat anti-mouse lgM APC (1 :4) Thermo Scientific hVB3.1 FITC (1:10); luor 647® Goat anti-mouse lgG (1:100) Beckman Coulter hVB3 FITC lgM (1:10); Goat anti-mouse lgM APC (1:4) Thermo Scientific hVB3.1 FITC (1:10); AlexaFluor® 647 Goat anti-mouse lgG (1:100) n Coulter hVB3 FITC lgM (1:10); Goat ouse lgM APC (1:4) Using thermal denaturation s, we have identified these antibodies to recognize folded epitopes on V03 (data not shown). Signals were amplified using AlexaFluor® 647 Goat anti-mouse lgG (Life Technologies) and Goat anti-mouse lgM APC (lnvitrogen) secondary antibodies. During 3 iterative sorts, a VB3-positively staining population emerged (Figure 5A). ing the 3rd sort, a clone called WT1- D13 was isolated for improved V[33 fluorescence (Figure SB) and showed thermal stability when heated to 80 °C (data not shown). The WT1-D13 clone was used as a template for affinity maturation.

EXAMPLE 5 CDR10I LIBRARY CONSTRUCTION AND SELECTION OF A WT1 TCR WITH ENHANCED BINDING TO WT1:HLA.A2, WT1.1 ] The stabilized 3 clone isolated from selection of error-prone PCR ies was used as a template for generation of a CDR10I library spanning 4 nt residues via splicing by overlap extension (SOE)(Horton et al. (1990) Biotechniques, 8, 528-535). The human WT1-D13 CDR10I scTCR library was thus introduced into the yeast display vector by combining the linearized pCT302 vector, WT1—D13 CDR10I y PCR product, and competent EBY100 yeast cells. The ant library contained about 3.1 X 106 independent clones, was judged by plating limiting dilution aliquots of yeast after electroporation. The WT1-D13 CDR10I library were FACS sorted according to the Table 2 for binding to WT1 (RMFPNAPYL, SEQ ID NO:6)/HLA.A2/lg dimers (BD DimerX).

Table 2. Sorting Conditions 1 100 nM WT1:HLA.A2 dimer APO—conjugated goat anti-mouse secondary antibody (1:100) 2 100 nM WT1:HLA.A2 dimer APO—conjugated goat ouse secondary dy (1:100) 3 100 nM WT1:HLA.A2 dimer APO—conjugated goat anti-mouse secondary antibody (1:100) 4 100 nM WT1:HLA.A2 dimer APO—conjugated goat anti-mouse secondary antibody (1:100) 200 nM WT1:HLA.A2 dimer APO—conjugated goat anti-mouse secondary antibody (1:100) After five rounds of selection by FACS with WT1 (RMFPNAPYL, SEQ ID NO:6)/HLA-A2/lg dimers, a modestly positively staining population began to emerge (Figure 6A). Clone 3.1, isolated following the 5th sort, showed a modest binding improvement to WT1 (RMFPNAPYL, SEQ ID HLA.A2 and was used as a template for further affinity maturation (Figure 6B).

EXAMPLE 6 CDR3 LIBRARY CONSTRUCTION AND SELECTION OF A WT1 TCR WITH FURTHER ENHANCED BINDING TO WT1:HLA.A2,WT1.1.1 In order to further improve the affinity of the WT1 scTCR, CDR3 libraries were generated using the WT1-D13.1 clone isolated from the WT1-D13 CDR10I y as a template. The WT1-D131 CDR3 libraries were generated by splicing by overlap extension (SOE) PCR, making degenerate codons spanning 5 adjacent codons in each CDR3 at a time (2 libraries in the CDR3[3 loop; 2 in the CDR30I loop). Each WT1-D131 CDR3 library was thus introduced into the yeast y vector by combining the linearized pCT302 vector, WT1-D131 CDR3 PCR product (i.e. 1, CDR30I2, CDR3B1, or CDR3B2 library), and competent EBY100 yeast cells. The four resultant libraries were pooled and the ant ed library contained about 3.5 X 106 ndent clones as determined by plating limiting dilution aliquots of yeast after electroporation. The WT1-D13 CDR3 combined ies were FACS sorted according to the chart in Table 3 for binding to WT1 (RMFPNAPYL, SEQ ID NO:6)/HLA.A2/lg dimers (BD DimerX).

Table 3. Sorting Conditions 1 100 nM WT1:HLA.A2 dimer APO-conjugated goat ouse secondary antibody (1:100) 2 100 nM WT1:HLA.A2 dimer APO-conjugated goat anti—mouse secondary antibody ) 3 10 nM WT1:HLA.A2 dimer APO-conjugated goat ouse secondary antibody (1:100) After three rounds of selection by FACS with WT1 (RMFPNAPYL, SEQ ID NO:8)/HLA—A2/Ig dimers, a positively staining population began to emerge (Figure 7A). Clone WT1-D13.1.1, isolated following the 3rd sort, showed increased binding to WT1 (RMFPNAPYL, SEQ ID NO:8)/HLA.A2 (Figure 7B).

EXAMPLE 7 BINDING ANALYSIS OF HIGH AFFINITY WT1 TCR,WT1-D13.1.1 In order to assess the binding of the WT1-D13.1.1 clone isolated from selections of CDR3 libraries, yeast ying the WT1-D13.1 .1 were titrated with WT1 (RMFPNAPYL, SEQ ID NO:6)/HLA.A2 dimers HLA-A2-lg) and monomers expressed and purified from Eco/i. The WT-1/A2 dimers were assayed at 160 pM to 500 nM (Figure 8A), and the monomers were assayed at 6.4 nM to 4 uM (Figure SB).

Yeast cells were then washed and analyzed by flow cytometry. Mean fluorescence intensity (MFI) were d for each histogram versus the concentration of the WT- A2 x. Values were normalized using nonlinear regression analysis and Knapp values of 25 nM and 240 nM were determined for dimmer and monomer, respectively (Figure 8C and 8D). Thus the WT1-D13.1.1 exhibited nanomolar affinity.

EXAMPLE 8 BINDING IS OF SOLUBLE HIGH AFFINITY WT1 TCR,WT1-D13.1.1 To further Show that the WT1-D13.1 .1 sch specifically bound WT1/HLA-A2 with high-affinity, a soluble form of WT1-D13.1 .1 sch was expressed and refolded from E. coli inclusion bodies and biotinylated via a C-terminal BirA tag (Aggen et al. (2011) Protein Engineering, Design, & Selection, 24, 361-72; Zhang et al. (2007) J Exp Med, 204, 49-55). The human cell line T2 (HLA-A2+) was incubated with 1 uM Tax, MART-1, or WT1 es and washed. Biotinylated WT1—D13.1 .1 sch was titrated on T2 cells aded without peptide e 9A), or with the negative peptide Tax (4 nM to 1 uM) (Figure QB), null peptide MART-1 (4 nM to 1 uM) (Figure 9C), WT1 (4 nM to 1 uM) (Figure 9D). The cells were washed and incubated with SA-PE and analyzed by flow cytometry. Only cells loaded with WT1 peptide were bound by the WT1-D13.1.1 TCR (Figure 9A-D) showing that the soluble TCR was specific for WT1. Non-linear regression of the plot of MFI versus TCR concentration of the WT1 ion showed that the soluble TCR exhibited a minimum KD value of 260 nM (Figure 9E).

EXAMPLE 9 SEQUENCE ANALYSIS OF THE ISOLATED TCRS FOR IMPROVED TY AGAINST THE WT1 ANTIGEN Sequences of the WT1-specific (P22, D13, D13.1, D13.0.1 and D13.1.1) single-chain TCRs were determined from isolated plasmids, and are shown in Figure 1. The amino acid sequences of the VB chain of P22, D13, D13.1, D13.0.1 and D13.1.1 are set forth in SEQ ID NOs:1, 21, 21, 3 and 3, respectively, and the amino acid sequences of the VOI chain of P22, D13, D13.1, D13.0.1 and D13.1.1 are set forth in SEQ ID NOs:2, 22, 4, 2, and 4, respectively. Note that D13.0.1 was constructed by removing the CDR10I mutations from the final affinity matured scTCR D13.1.1 (SEQ ID NO: 5). The underlined amino acid ons in Figure 1 indicate mutations that arose from error-prone library selections for stabilizing mutations.

The amino acid positions in boxes show the ty enhancing mutations that were selected from CDR libraries.

EXAMPLE 10 IN VITRo ACTIVITY OF THE WT1-P22, WT1-D131, WT1-D13.0.1 AND WT1-D13.1.1 TCRs IN CD8 AND CD4 T CELLS To assess the ty of the different WT1-specific TCRs in T cells, CD8 (Figure 10A) and CD4 (Figure 108) T cells were isolated from AAD transgenic mice (these are mice that have a hybrid class I gene ting of the (11 and (12 s of HLA-A2 and the Q3 domain of the mouse Db; these AAD mice are available from Jackson Laboratories). The cells were activated with beads coupled with anti-CD3 and anti-CD28 antibodies and then transduced with the WT1-P22, WT1-D13.1, WT1- D13.0.1 and WT1—D13.1.1 TCRs (sequences did not contain the D13 stabilizing mutations, VB F488 and D51 G), as described in Chervin et al, (2013) Gene Ther. (6):634-44. T cells were incubated with different concentrations of the peptide WT1 and AAD blast cells prepared by avilin A stimulations of splenic cells from AAD mice. After a 24-hour incubation, atants were analyzed for lFN-v concentration using an ELISA. CD8 T cells showed the greatest activity with the D13.0.1 and D13.1.1 TCRs (Figure 10A). CD4 T cells were only activated with the 1 TCR, showing that D13.1.1 can mediate activity ndently of CD8 (Figure 108). No reactivity has been observed with other HLA-A2 g peptides such as MART1.

EXAMPLE 11 WT1-D13.1.1 TCR IN CD8 T CELLS ARE NOT REACTIVE WITH HUMAN PEPTIDES THAT ARE STRUCTURALLY SIMILAR TO WT1 To further determine the specificity of the high-affinity WT1-D13.1.1 TCR, in vitro activity with peptides structurally similar to the WT1 peptide was ed. A proteome search was conducted for peptides urally similar to the WT1 peptide, based on conservative mutations at the 9 residues of WT1. Peptides present in the human proteome were then accessed for g ability to HLA-A2 via prediction algorithms. The ten peptides that were predicted to bind HLA-A2 with the highest affinity (Figure 11) were synthesized and tested for ability to activated CD8 T cells transduced with the high-affinity WT1-D13.1 .1 TCR. None of these peptides displayed activity, suggesting that this TCR maintains specificity when presented with these 10 structurally similar peptides.

EXAMPLE 12 THERAPEUTIC FORMATS OF THE WT1, WT1-D13.1 AND WT1-D13.1.1 TCRs It is now well known that higher affinity TCRs can be used in various formats for ing cells that express the corresponding antigen. Thus, it is clear that the TCRs generated from the engineering strategies shown above can be used either in soluble form or in TCR gene therapy for adoptive T cell ies, as illustrated in Figure 12.

Materials and methods Antibodies, peptidezHLA-A2, MACSI and Flow Cytometry Reagents Antibodies used to detect yeast surface expression included: anti-HA e tag (Clone HA.11; Covance), anti-hVB3 FITC dy (Clone CH92; Beckman-Coulter), anti-hVB3.1 FITC antibody (Clone 8F10; Thermo Scientific), anti- hVBZO antibody (Clone ELL1.4; Beckman-Coulter), anti-V02 monoclonal antibody ted in our laboratory (data not shown), Goat-anti-mouse lgM APC (Life logies), Goat-anti-mouse lgG F(ab’)2 AlexaFluor® 647 secondary antibody (Invitrogen), Streptavidin-phycoerythrin (SA:PE, BD ngen), and MACS microbeads nyl Biotec).

Peptides that bind to HLA-A2 [WT1126_134: RMFPNAPYL (SEQ ID NO:6) were synthesized by standard F-moc fluorenyl)methoxycarbonyl) chemistry at the Macromolecular Core Facility at Penn State sity College of Medicine (Hershey, PA, USA). For FACS and flow cytometry analysis, recombinant soluble dimeric HLA—A2:lg fusion protein (BDT'V' DimerX) was used. Additionally, a monomeric HLA.A2-biotin reagent generated by the exchange of a UV-cleavable peptide for another HLA.A2—restricted peptide in the ce of UV light was utilized for flow cytometry and MACS selections ko et al. (2006) Nat , 1, 1120- 1132; Toebes et al. (2006) Nat Med, 12, 246-251).

Cloning and expression of sch in yeast display s TCR variable region fragments (sch) were expressed in yeast y plasmid pCT302 (VB-L-Vd) (Boder and Wittrup (2000) Methods Enzymol, 328, 430- 444), which contains a galactose-inducable AGA2 fusion allowing for growth in Trp media. Induction of the sch gene involves growth of the transformed EBY100 yeast cells to nary phase in selection media followed by transfer to galactose- ning media. The template WT1 single-chain TCR gene was synthesized by Genscript (Piscataway, NJ, USA) with a F498 mutation in the Vd2—domain of the construct (Aggen et al. (2011) Protein Eng Des Sel, 24, 361-372).

The WT1—specific TCR genes were isolated from CTL clones (TCR genes against WT1 from Phillip Greenberg; e.g. Dossett et al. (2009) Mol Ther. 17(4), 742) and the genes were synthesized by ipt, cloned as a single-chain format (V8- linker—Va), introduced into a yeast display vector for expression on the surface of yeast. The schs consisted of the variable contains attached by the linker region GSADDAKKDAAKKDGKS (SEQ ID NO:8) (Hoo et al. (1992) Proc Natl Acad Sci USA, 89, 4759-4763; Weber et al. (2005) Proc Natl Acad Sci USA, 102, 19033— 19038; Aggen et al. (2011) Protein Eng Des Sel, 24, 361-372). The sch was introduced into the Nhel and Xhol restrictions sites of pCT302.

Generation, display, and selection of mutated sch yeast display ies Error-prone PCR was used to generate random mutations, as previously described (Richman et al. (2009) Mol Immunol, 46, 902-916). CDR1 and 3 libraries were generated using Splicing by p extension (SOE) PCR spanning 4-5 adjacent codons at a time (Horton et al. (1990) Biotechniques, 8, 528-535).

For the WT1-D13 CDR1or library, pre-SOE PCR products were generated utilizing the following primer pairs: 5' - GGC AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) (SEQ ID NO:9) and 5’ - ACG ATC GCT ATA GGT GCA GTT CAA TGA TGC AAT AGC ACC TTC CGG GAC ACT TAA TGG GCC GCT - 3’(SEQ ID NO:10), and 5’ — ATT GCA TCA TTG AAC TGC ACC TAT AGC GAT CGT NNS NNS NNS MTTC TTT TGG TAT AGA CAG TAC AGT GGC AAA TCC CCG — 3’ (SEQ ID NO:11) and 5'— TAA TAC GAC TCA CTA TAG CG —3' (T7) (SEQ ID NO:12). SOE PCR was performed with each ponding Pre-SOE along with both T7 and Splice 4L.

For the 3.1 CDR3 libraries, pre-SOE PCR products were generated for each of the four libraries utilizing the following primer pairs: B1: 5' - GGC AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) (SEQ ID NO:9). and 5’ — TGC ACA CAG GTA CAT GGA AGT TTG ATT GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA ACG TTC TTT — 3’ (SEQ ID NO:13), and 5’ — AGT ACC AAT CAA ACT TCC ATG TAC CTG TGT GCA NNS NNS NNS NNS NNS GAA CAG TTT TTC GGC CCA GGT ACA AGA TTA ACG GTG — 3’ (SEQ ID NO:14) and 5'- TAA TAC GAC TCA CTA TAG CG -3' (T7) (SEQ ID NO:12); B2: Splice 4L (SEQ ID NO:9) and ’ — TGC ACA CAG GTA CAT GGA AGT TTG ATT GGT ACT AGC GCT TTC CAG AAT CAA ACT GAA ACG TTC TTT — 3’ (SEQ ID NO:15), and 5’ — AGT ACC AAT CAA ACT TCC ATG TAC CTG TGT GCA AGC AGT TCC ATC NNS NNS NNS NNS MGGC CCA GGT ACA AGA TTA ACG GTG — 3’ (SEQ ID NO:16) and T7 (SEQ ID NO:12); o1: Splice 4L (SEQ ID NO:9) and 5’ — GGC GCA CAG GTA AGT GGC GCT ATC TGA CGG TTG GCT ATC ACG GAT TAA CAG AGA GAC ATA CTG GGA — 3’ (SEQ ID NO:17), and 5’ — CAA CCG TCA GAT AGC GCC ACT TAC CTG TGC GCC NNS NNS NNS NNS NNS AAT ATG CTG ACC TTC GGT GGC GGT ACT CGC TTA ATG — 3’ (SEQ ID NO:18) and T7 (SEQ ID ; a2: Splice 4L (SEQ ID NO:9) and 5’ — GGC GCA CAG GTA AGT GGC GCT ATC TGA CGG TTG GCT ATC ACG GAT TAA CAG AGA GAC ATA CTG GGA — 3’ (SEQ ID NO:19), and ’ — CAA CCG TCA GAT AGC GCC ACT TAC CTG TGC GCC GCG AAT AAC GCG NNS NNS NNS NNS NNS TTC GGT GGC GGT ACT CGC TTA ATG — 3’ (SEQ ID N020) and T7 (SEQ ID NO:12).

Yeast libraries were made by homologous recombination in EBY100 yeast by electroporating error prone or SOE PCR products along with Nhel and Xhol digested pCT302 (Horton et al. (1990) Biotechniques, 8, 528-535). The libraries were induced in galactose-containing media (SG-CAA) for 48 h, washed with 1 mL 1% PBS/BSA, and stained with antibodies or peptide:MHC reagents at the concentrations indicated in Figures 4A, 5A, 6A, 8A, and 9A. Cells were washed (1 ml, 1% PBS/BSA), and the most fluorescent cells were selected using a FACS Aria (BD ence) high-speed sorter or via MACS LS columns on a QuadroMACST'V' tor (Miltenyl Biotec). In order to test thermal stability of isolated clones, yeast were incubated at elevated temperature for 30 min prior to the staining protocol (data not shown).

Isolation and staining of high ty clones Following selections, library clones were isolated by plating limiting dilutions. es were expanded and induced in galactose-containing media (SG- CAA) for 48 hours, washed with 1 mL 1% PBS/BSA, and stained with various concentrations of peptide/HLA.A2 DimerX, goat-anti-mouse lgG F(ab’)2 luor® 647 secondary antibody, or various concentrations of UV-exchanged e/HLA.A2, SA-PE. Cells were washed (1 ml, 1% PBS/BSA) and analyzed on an Accuri C6 flow cytometer.

Plasmids were recovered using ZymoprepTIVI Yeast Plasmid Miniprep |l (Zymo Research) and introduced back into E. coli via heat shock transformation into Subcloning EfficiencyTM DH5qT'V' Competent Cells (lnvitrogen). E. coli cells were expanded and ds were isolated using QlAprep Spin Miniprep Kit (Qiagen).

Sequences of individual clones were determined by Sanger sequencing STATEMENTS REGARDING INCORPORATION BY NCE AND VARIATIONS All references cited herein, for example patent nts including issued or d patents or equivalents; patent application publications; and nonpatent literature documents or other source al; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each nce is at least partially not inconsistent with the disclosure in this application (for example, a reference that is lly inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the disclosure pertains.

References cited herein are incorporated by reference herein in their entirety to indicate the state of the art, in some cases as of their filing date, and it is intended that this information can be employed herein, if needed, to exclude (for example, to disclaim) ic embodiments that are in the prior art or to use s or materials that are in the state of the art without the specific inclusion of the methods or materials in the disclosure herein. For example, when a compound is claimed, it should be understood that compounds known in the prior art, ing certain nds disclosed in the references disclosed herein cularly in nced patent documents), are not intended to be included in the claim.

When a Markush group or other grouping is used herein, all individual members of the group and all combinations and binations possible of the group are intended to be individually included in the disclosure.

Where the terms ise”, “comprises”, “comprised”, or “comprising” are used herein, they are to be interpreted as specifying the ce of the stated features, integers, steps, or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component, or group thereof. Separate embodiments of the disclosure are also intended to be assed n the terms “comprising” or “comprise(s)” or “comprised” are optionally replaced with the terms, analogous in grammar, e.g.; “consisting/consist(s)” or “consisting essentially of/consist(s) essentially of” to thereby describe further embodiments that are not necessarily nsive. For clarification, as used herein “comprising” is synonymous with “having,” "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude onal, unrecited elements or method steps. As used herein, sting of" excludes any element, step, component, or ingredient not specified in the claim element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim (e.g., not affecting an active ingredient). In each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The disclosure illustratively described herein suitably may be practiced in the absence of any element or ts, limitation or limitations which is not specifically disclosed herein.

The disclosure has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the sure. It will be appreciated by one of ordinary skill in the art that compositions, methods, devices, device elements, materials, optional features, procedures and ques other than those specifically described herein can be applied to the practice of the disclosure as broadly disclosed herein without resort to undue experimentation. All art-known functional equivalents of compositions, methods, devices, device elements, als, procedures and techniques bed herein; and ns thereof; are intended to be encompassed by this disclosure.

Whenever a range is disclosed, all subranges and individual values are intended to be encompassed. This disclosure is not to be limited by the embodiments disclosed, including any shown in the drawings or exemplified in the specification, which are given by way of example or illustration and not of limitation. Some references ed herein are orated by reference herein to e details concerning additional starting materials, additional methods of synthesis, and additional methods of analysis and onal uses of the disclosure.

One d in the art would readily appreciate that the present disclosure is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those nt therein. The compositions and methods and accessory methods described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the disclosure. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the disclosure.

NCES 1. Addo M. M., Draenert R., Rathod A., Verrill C. L., Davis B. T., Gandhi R. T., Robbins G. K., Basgoz N. 0., Stone D. R., Cohen D. E., Johnston M. N., Flynn T., Wurcel A. G., Rosenberg E. 8., Altfeld M. and Walker B. D. (2007) Fully Differentiated HIV-1 Specific CD8+ T Effector Cells Are More Frequently Detectable in Controlled than in Progressive HIV—1 Infection. PLoS ONE 2, e321. 2. Aggen D. H., Chervin A. 8., lnsaidoo F. K., Piepenbrink K., H., Baker B. M. and Kranz D. M. (2011) Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein ering, Design, & Selection 24, 361-72. 3. Anikeeva N., Mareeva T., Liu W. and Sykulev Y. (2009) Can eric T- cell or be used as a tool to detect viral peptide epitopes on infected cells? Clin Immunol 130, 98-109. 4. Armstrong K. M., Piepenbrink K. H. and Baker B. M. (2008) Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes.

Biochem J 415, . . ld R. and Jakobsen B. K. (2006) Making ffinity T-cell receptors: a new class of targeted therapeutics. lDrugs 9, 554-9. 6. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmuller G., Reinhardt C., Baeuerle P. A. and Kufer P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. e 321, 974-7. 7. Benatuil L., Perez J. M., Belk J. and Hsieh C. M. (2010) An improved yeast transformation method for the generation of very large human antibody libraries.

Protein Eng Des Sel 23, 155—9. 8. Bird R. E., Hardman K. D., Jacobson J. W., Johnson 8., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S. and Whitlow M. (1988) Single-chain antigen-binding proteins. Science 242, 423-426. 9. Boder E. T. and p K. D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat. h. 15, 553-557.

. Boder E. T. and Wittrup K. D. (2000) Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 328, 430-44. 11. Boon T. and Old L. J. (1997) Cancer tumor ns. Curr Opin Immunol 9, 681-3. 12. Borbulevych O. Y., Santhanagopolan S. M., Hossain M. and Baker B. M. (2011) TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol 187, 2453-63. 13. Brower V. (1997) Enbrel's phase III reinforces prospects in RA [news]. Nat Biotechnol 15, 1240. 14. Bulek A. M., Cole D. K., a A., Dolton G., Gras 8., Madura F., Fuller A., Miles J. J., Gostick E., Price D. A., Drijfhout J. W., Knight R. R., Huang G. C., Lissin N., Molloy P. E., Wooldridge L., Jakobsen B. K., Rossjohn J., Peakman M., Rizkallah P. J. and Sewell A. K. (2012) Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol 13, 283-9.

. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman |., ville S. A., Viner J. L., Weiner L. M. and Matrisian L. M. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15, 5323-37. 16. Chervin A. S., Aggen D. H., Raseman J. M. and Kranz D. M. (2008) Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods 339, 175-84. 17. Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, and Kranz DM. (2013) Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther. 20(6):634-44 18. Colby D. W., g B. A., Graff C. P., Yeung Y. A., Swers J. S. and Wittrup K. D. (2004) Engineering dy affinity by yeast surface display. Methods Enzymol 388, . 19. Davis M. M. and Bjorkman P. J. (1988) T-cell antigen receptor genes and T-cell recognition. Nature 334, 395—402.

. Davis M. M., Boniface J. J., Reich Z., Lyons D., Hampl J., Arden B. and Chien Y. (1998) Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 16, 523-544. 21. Ding Y. H., Baker B. M., Garboczi D. N., Biddison W. E. and Wiley D. C. (1999) Four A6—TCR/peptide/H LA-A2 ures that generate very different T cell signals are nearly identical. Immunity 11, 45-56. 22. Foote J. and Eisen H. N. (2000) ng the affinity g for dies and T cell receptors. Proc Natl Acad Sci U S A 97, 81. 23. zi D. N., Ghosh P., Utz U., Fan Q. R., Biddison W. E. and Wiley D.

C. (1996) Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134-141. 24. Garcia K. C., Adams J. J., Feng D. and Ely L. K. (2009) The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 10, 143—7.

. Haidar J. N., Pierce B., Yu Y., Tong W., Li M. and Weng Z. (2009) Structure-based design of a T—cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins 74, 948-60. 26. Harkiolaki M., Holmes S. L., Svendsen P., Gregersen J. W., Jensen L. T., McMahon R., Friese M. A., van Boxel G., Etzensperger R., Tzartos J. S., Kranc K., Sainsbury S., Harlos K., Mellins E. D., Palace J., Esiri M. M., van der Merwe P. A., Jones E. Y. and Fugger L. (2009) T cell-mediated autoimmune disease due to low- affinity eactivity to common microbial peptides. Immunity 30, 348-57. 27. Hawse W. F., on M. M., Joyce M. V., Hellman L. M., Hossain M., Ryan V., Pierce B. G., Weng Z. and Baker B. M. (2012) Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J Immunol 188, 5819-23. 28. Holler P. D., cki L. K. and Kranz D. M. (2003) TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 4, 55—62. 29. Holler P. D., Holman P. 0., Shusta E. V., O'Herrin S., p K. D. and Kranz D. M. (2000) In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A 97, 5387—92.

. Holliger P., Prospero T. and Winter G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 90, 6444-8. 31. Hoogenboom H. R. (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23, 1105—16. 32. Jarvis L. M. (2012) Rethinking Antibody-Drug Conjugates. Chemical and Engineering News 90, 12-18. 33. Kessels H. W., van Den Boom M. D., Spits H., erg E. and Schumacher T. N. (2000) Changing T cell specificity by retroviral T cell receptor y. Proc Natl Acad Sci U S A 97, 14578—83. 34. Kieke M. C., Shusta E. V., Boder E. T., Teyton L., p K. D. and Kranz D. M. (1999) Selection of functional T cell receptor mutants from a yeast surface- display library. Proc Natl Acad Sci U S A 96, 5651—6.

. Lauck F., Smith C. A., Friedland G. F., Humphris E. L. and Kortemme T. (2010) RosettaBackrub--a web server for flexible backbone protein structure modeling and design. Nucleic Acids Res 38, W569-75. 36. Li Y., Moysey R., Molloy P. E., Vuidepot A. L., Mahon T., Baston E., Dunn S., Liddy N., Jacob J., Jakobsen B. K. and Boulter J. M. (2005) Directed evolution of human T-cell receptors with picomolar ties by phage display. Nat Biotechnol 23, 349-54. 37. Liddy N., Bossi 6., Adams K. J., Lissina A., Mahon T. M., Hassan N. J., et J., Bianchi F. C., ey N. J., Ladell K., Gostick E., Sewell A. K., Lissin N. M., Harwood N. E., Molloy P. E., Li Y., Cameron B. J., Sami M., Baston E. E., Todorov P. T., Paston S. J., Dennis R. E., Harper J. V., Dunn S. M., ld R., Johnson A., McGrath Y., Plesa G., June C. H., Kalos M., Price D. A., Vuidepot A., Williams D. D., Sutton D. H. and Jakobsen B. K. (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med. 38. -Greenfeld D. and Benhar l. (2012) Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Deliv Rev. 39. Manning T. C. and Kranz D. M. (1999) Binding energetics of T—cell receptors: correlation with immunological consequences. Immunology Today 20, 417-422. 40. Marrack P., Scott-Browne J. P., Dai S., Gapin L. and Kappler J. W. (2008) Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 26, 171-203. 41. Marsh S. G. E., Parham P. and Barber L. D. (2000) The HLA Facts Book.

Academic Press, . 42. Mason D. (1998) A very high level of eactivity is an essential e of the T- cell or. Immunol Today 19, 395-404. 43. Miller B. R., Demarest S. J., Lugovskoy A., Huang P, Wu X., Snyder W. B., Croner L. J., Wang N., Amatucci A., Michaelson J. S. and Glaser S. M. (2010) Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 23, 549-57. 44. Molloy P. E., Sewell A. K. and Jakobsen B. K. (2005) Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol 5, 438-43. 45. Murphy K. (2012) Janeway's immunobiology. Garland Science, New York. 46. Nold M. F., Nold-Petry C. A., Zepp J. A., Palmer B. E., Bufler P. and Dinarello C. A. (2010) lL-37 is a ental inhibitor of innate immunity. Nat Immunol 11,1014-22. 47. Pastan l., Hassan R., Fitzgerald D. J. and Kreitman R. J. (2006) lmmunotoxin therapy of cancer. Nat Rev Cancer 6, 559-65. 48. Pierce B. G., Haidar J. N., Yu Y. and Weng Z. (2010) Combinations of ty—enhancing mutations in a T cell receptor reveal highly nonadditive s within and between complementarity determining regions and chains. Biochemistry 49, 7050-9. 49. Porter D. L., Levine B. L., Kalos M., Bagg A. and June C. H. (2011) Chimeric antigen receptor—modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725-33. 50. Reichert J. M. and Valge—Archer V. E. (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6, 349-56. 51. Ricart A. D. and Tolcher A. W. (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4, 245-55. 52. Richman S. A., Aggen D. H., Dossett M. L., eyer D. L., Allen P. M., Greenberg P. D. and Kranz D. M. (2009) Structural es of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol 46, 902-16. 53. Richman S. A. and Kranz D. M. (2007) Display, engineering, and applications of antigen-specific T cell receptors. Biomol Eng 24, 361-73. 54. Rock K. L. and Goldberg A. L. (1999) Degradation of cell ns and the generation of MHC class I- presented peptides. Annu Rev Immunol 17, 739-79. 55. Rudolph M. G., Stanfield R. L. and Wilson |. A. (2006) How TCRs bind MHCs, peptides, and ptors. Annu Rev Immunol 24, 419-66. 56. Sadelain M., Brentjens R. and Riviere l. (2009) The e and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21, 215-23. 57. Sami M., Rizkallah P. J., Dunn S., Molloy P., Moysey R., Vuidepot A., Baston E., Todorov R, Li Y., Gao F., Boulter J. M. and Jakobsen B. K. (2007) Crystal structures of high affinity human T-cell receptors bound to e major histocompatibility complex reveal native diagonal binding geometry. Protein Eng Des Sel 20, 397—403. 58. Schrama D., Reisfeld R. A. and Becker J. C. (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5, . 59. Scott J. K. and Smith G. P. (1990) Searching for peptide ligands with an epitope library. Science 249, . 60. Skowera A., Ellis R. J., Varela-Calvino R., Arif S., Huang G. C., Van-Krinks C., a A., Rackham C., Allen J. 8., Tree T. |., Zhao M., Dayan C. M., Sewell A.

K., Unger W. W., out J. W., Ossendorp F., Roep B. O. and Peakman M. (2008) CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 118, 3390- 402. 61. Smith C. A. and me T. (2008) Backrub-like backbone simulation recapitulates natural protein conformational variability and improves mutant side- chain prediction. J Mol Biol 380, 742-56. 62. 800 Hoo W. F., Lacy M. J., Denzin L. K., Voss E. W. J., n K. D. and Kranz D. M. (1992) Characterization of a single-chain T cell receptor expressed in E.

Coli. Proc. Natl. Acad. Sci. 89, 4759-4763. 63. Starr T. K., Jameson S. C. and Hogquist K. A. (2003) Positive and negative selection ofT cells. Annu Rev Immunol 21, 139-76. 64. Starwalt S. E., Masteller E. L., one J. A. and Kranz D. M. (2003) Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng 16, . 65. Stone J. D., Chervin A. S., Aggen D. H. and Kranz D. M. (2012) T cell receptor engineering. Methods Enzymol 503, 189-222. 66. Stone J. D., Yin Y., Mo M., Weber K. S., eyer D. L., Allen P. M., Mariuzza R. A. and Kranz D. M. (2012) Engineering High-Affinity T Cell Receptor/ Cytokine Fusions for Therapeutic Targeting. ln Protein Engineering (Edited by Kaumaya P.). lnTech. 67. Stroncek D. F., Berger C., Cheever M. A., Childs R. W., Dudley M. E., Flynn P., Gattinoni L., Heath J. R., Kalos M., Marincola F. M., Miller J. S., Mostoslavsky 6., Powell D. J., Jr., Rao M., Restifo N. P., Rosenberg S. A., O'Shea J. and Melief C. J. (2012) New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 10, 48. 68. Swers J. S., Kellogg B. A. and p K. D. (2004) Shuffled antibody libraries d by in vivo homologous ination and yeast surface display.

Nucleic Acids Res 32, e36. 69. Tayal V. and Kalra B. S. (2008) Cytokines and anti-cytokines as therapeutics——an update. Eur J Pharmacol 579, 1-12. 70. Thakur A. and Lum L. G. (2010) Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 12, 340-9. 71. Tonegawa S. (1988) Nobel lecture in logy or medicine--1987.

Somatic generation of immune diversity. In Vitro Cell Dev Biol 24, 253-65. 72. Tsomides T. J., Aldovini A., Johnson R. P., Walker B. D., Young R. A. and Eisen H. N. (1994) Naturally sed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 180, 1283-93. 73. Turner D. J., Ritter M. A. and George A. J. (1997) Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods 205, 43-54. 74. Utz U., Banks D., Jacobson S. and Biddison W. E. (1996) Analysis of the T- cell receptor repertoire of human T—cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T cytes from patients with HTLVassociated disease: evidence for oligoclonal expansion. J Virol 70, . 75. Varela-Rohena A., Molloy P. E., Dunn S. M., Li Y., Suhoski M. M., Carroll R. G., Milicic A., Mahon T., Sutton D. H., Laugel B., Moysey R., Cameron B. J., ot A., Purbhoo M. A., Cole D. K., Phillips R. E., June C. H., Jakobsen B. K., Sewell A. K. and Riley J. L. (2008) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14, 1390-5. 76. Weber K. S., eyer D. L., Allen P. M. and Kranz D. M. (2005) Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc Natl Acad Sci U S A 102, 19033-8. 77. Wong R. L., Liu B., Zhu X., You L., Kong L., Han K. P., Lee H. |., Chavaillaz P. A., Jin M., Wang Y., Rhode P. R. and Wong H. C. (2011) Interleukin- :lnterleukin—15 receptor alpha scaffold for creation of multivalent targeted immune molecules. Protein Eng Des Sel 24, 373-83.

U.S. s 7,569,357; Filed 20—Feb-04; Issued 4-Aug-09; Board of Trustees University of Illinois. High affinity TCR proteins and methods. 7,465,787; Filed 16—Dec-03; Issued 16-Dec-08; Board of Trustees University of Illinois. Yeast cell surface display of ns and uses therof. 6,759,243; Filed 6-Dec-00; Issued 6-Jul-04; Board of Trustees University of Illinois.

High affinity TCR proteins and methods. 6,699,658; Filed 20—Jan-98 ; Issued 2—Mar-04; Board of Trustees University of Illinois. Yeast cell surface y of ns and uses therof. 6,696,251; Filed 28—Nov-00; Issued 24-Feb—04; Board of Trustees sity of is. Yeast cell e display of proteins and uses therof. 6,423,538; Filed 28—Nov-00; Issued 23-Jul—02; Board of Trustees University of Illinois. Yeast cell surface y of proteins and uses therof. 6,300,065; Filed 26-Aug—98; Issued 9-Oct—01; Board of Trustees University of is. Yeast cell surface display of proteins and uses therof. 8,143,376; Filed 18-May—05; Issued 27-Mar-12; Immunocore Limited; High affinity NY-ESO T cell receptor. 8,088,379; Filed -07; Issued 3-Jan-12; Immunocore Limited; Modified T cell receptors and related materials and methods. 8,017,730; Filed -06; Issued 13-Sep-11; Immunocore Limited; T cell receptors which bind to WGFVRACL-HLA-A24. 7,763,718; Filed 29-Oct-07; Issued 27-Jul-10; Immunocore Limited; Soluble T cell receptors. 604; Filed 9-Jul-03; Issued 23-Feb-10; Immunocore Limited; Modified soluble T cell receptor. 410; Filed 7-Oct—08; Issued 27-Oct-09; Immunocore Limited; Method of improving T cell receptors. 7,569,664; Filed 3-Oct—03; Issued 4-Aug-09; Immunocore Limited; Single chain recombinant T cell receptors. 8,105,830; Filed 5-Nov-02; Issued 31-Jan—12; Altor Bioscience Corporation; Polyspecific binding molecules and uses therof. 6,534,633; Filed 21—Oct-99; 18-Mar-03; Altor ence Corporation; Polyspecific binding les and uses therof.

Claims (9)

The claims defining the invention are as s:

1. A ed T cell receptor, or n-binding nt thereof, comprising a V and a V derived from a wild type T cell receptor, n the V and V, respectively, comprise the amino acid sequence set forth in SEQ ID NOs:2 and 3; SEQ ID NOs:4 and 3; SEQ ID NOs:4 and 21; or SEQ ID NOs:22 and 21.

2. The modified T cell receptor of claim 1, wherein the modified T cell receptor comprises the V amino acid sequence set forth in SEQ ID NO:3 and the V amino acid sequence set forth in SEQ ID NO:4.

3. The modified T cell receptor of claim 1, wherein the modified T cell or ses a single-chain T cell receptor with the amino acid sequence set forth in SEQ ID NO:5.

4. The modified T cell receptor of claim 1, comprising the V amino acid sequence set forth in SEQ ID NO:2 and the V amino acid sequence set forth in SEQ ID NO:3.

5. The modified T cell receptor of any one of claims 1-4 that binds to a complex of the peptide WT1 and the HLA-A2 molecule with a nanomolar or higher affinity, wherein the modified T cell receptor binds the complex with a KD value less than or equal to 10-6 M.

6. The modified T cell receptor of any one of claims 1-4 that is in soluble form.

7. A therapeutic agent that targets cancer cells that express the WT1 antigen, wherein the therapeutic agent comprises the modified T cell receptor of any one of claims 1-6.

8. A therapeutic agent that targets cancer cells that express the WT1 antigen, wherein the therapeutic agent comprises an isolated human T cell that expresses the modified T cell receptor of any one of claims 1-5.

9. Use of the modified T cell receptor of any one of claims 1-6 or the therapeutic agent of claim 7 or claim 8 in the manufacture of a medicament for treating a t having a cancer that expresses the WT1 antigen. Zflwzzzz